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ABSTRACT 
 
INTRODUCTION: Obesity and its associated complications such as diabetes and 
cardiovascular disease are escalating worldwide. Cardiovascular mortality and 
the occurrence of heart failure following a myocardial infarction are increased 
among diabetics. A high caloric diet has been associated with specific metabolic 
alterations such as increased FA utilization and decreased glucose utilization. 
We therefore hypothesized that, in a rat model of diet-induced obesity, pathways 
involved in myocardial glucose utilization would be down regulated with 
simultaneous up regulation of FA utilization pathways and that this will lead to 
certain metabolic adaptations which will eventually become maladaptive. We 
aimed to elucidate mitochondrial oxidative capacity, biogenesis, and signaling 
pathways involved in substrate utilization and energy production in rats on the 
obesity inducing diet for a period of 8 or 16 weeks. 
 
METHODS: The diet of male Wistar rats (180-200 g) was supplemented with 
sucrose and condensed milk for 8 or 16 weeks (DIO) and compared to  
age-matched controls. We determined the fasting blood glucose and serum 
insulin levels, which was used to calculate the HOMA index. Furthermore, (i) A 
set of hearts were removed and freeze-clamped immediately. (ii) Isolated hearts 
were perfused with Krebs-Henseleit buffer (10 mM glucose), subjected to 
regional ischaemia by ligating the left anterior descending artery (35 min). After 
10 min reperfusion, the infarcted and non-infarcted zones were freeze-clamped 
separately. Isolated mitochondria prepared from fresh tissue were used to 
measure oxidative capacity using either glutamate or palmitoyl-L-carnitine as 
substrates and exposed to anoxia (20 min) /reperfusion and used in e- transport 
chain complex analysis. Additionally we determined (i) ATP production (HPLC), 
(ii) citrate synthase activity and quantity as measure of active mitochondria per 
mg of protein and (iii) PDH complex expression and activity (ELISA). Levels of 
GLUT1, GLUT 4, PGC-1α, PPARα, PKB/Akt, GSK-3, PTEN, AMPK and PI3K 
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activity were measured via Western blotting and Real-time PCR was used to 
measure the expression of PDK 4 and FAT/CD36. 
 
RESULTS: The blood glucose and serum insulin levels were significantly 
elevated in the diet group after 8 weeks of DIO.  The PPARα, PGC-1α and PDK 
4 levels were also significantly elevated in the diet group with no significant 
difference in the levels of any of the other proteins measured or the level of 
citrate synthase activity. After 16 weeks of DIO the citrate synthase, PTEN and p-
PI3K activity was significantly reduced and the %recovery after 
anoxia/reperfusion when using palmitoyl was significantly increased in the diet 
group. There was no change in mitochondrial oxidative function in both groups 
after 8 and 16 weeks, as well as no difference in ATP production during state 3 
respiration. 
 
CONCLUSION: The increased blood glucose and serum insulin levels as well as 
the increase in the HOMA index in the diet group after 8 weeks of DIO indicates 
that these obese animals were insulin resistant. An increase in the level of 
PPARα and PGC-1α expression indicates an early compensatory effect which 
facilitates enhanced fatty acid utilization. This is underscored by elevated levels 
of PDK 4. We could find no significant difference in the quantity of the PDH 
enzyme but there was a significant increase in the level of PDH activity in the diet 
group after 16 weeks of DIO.  Mitochondria from the 16 weeks DIO animals were 
able to withstand anoxia/reperfusion and showed no malfunctioning of the 
electron transport chain, despite a reduction in PI3K & PTEN activity and the 
presence of insulin resistance. Mitochondrial biogenesis does not seem to play a 
significant role in the heart‟s adaptive response as there was no increase in the 
citrate synthase activity in both groups. We conclude that the hearts from these 
obese and insulin resistant rats are coping well and have adapted metabolically 
to compensate for any reduction in glucose oxidation. It is plausible that this initial 
metabolic adaptation may become maladaptive as obesity progresses.  
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OPSOMMING 
 
INLEIDING: Vetsug en die geassosieerde komplikasies, naamlik diabetes en 
kardiovaskulêre siektes is besig om wêreldwyd toe te neem. Kardiovaskulêre 
sterftes en die voorkoms van hartversaking ná „n miokardiale infarksie is verhoog 
onder diabete. „n Dieet met „n hoë vetinname word ook geassosieer met 
spesifieke metabolise veranderings, soos verhoogde vetsuur gebruik en „n 
afname in glukoseverbruik. Ons het dus vermoed dat seintransduksie paaie 
betrokke by miokardiale glukose verbruik afgereguleer sal wees met tesame 
opreguleering van seintransduksie paaie betrokke by vetsuur verbruik, en dat dit 
sal lei tot sekere metaboliese aanpassings wat uiteindelik wanaanpaslik sal word.  
 
Ons DOESTELLING in hierdie studie was dus om meer lig te werp op 
mitokondriale oksidatiewe kapasiteit, biogenese, en seintransduksie betrokke by 
substraatverbruik en energieproduksie in rotte op die vetsugveroorsakende-dieet 
(vir „n tydperk van 8 tot 16 weke). 
 
METODE: Die dieet van die manlike Wistar rotte (180-200 g) is aangevul met 
sucrose en gekondenseerde melk vir 8 of 16 weke (DIO) en is dan vergelyk met 
kontrole rotte van dieselfde ouderdom. Die vastende bloedglukose-en 
insulienvlakke is bepaal en hierdie waardes is gebruik om die HOMA indeks te 
bereken. Verder is, (i) „n stel harte verwyder en onmiddelik gevriesklamp (ii) 
geïsoleerde harte met Krebs-Henseleit buffer (10 mM glukose) geperfuseer en 
dan aan 35 min streeksiskemie en 10 min herperfusie blottgestel. Na 10 min 
herperfusie, is die infarct en nie-infarktsones apart gevriesklamp. Geïsoleerde 
mitokonderieë is voorberei van vars weefsel en is gebruik a) om oksidatiewe 
kapasiteit te meet met behulp van glutamaat of palmitoiel-L-karnitien as substrate 
of b) blootgestel aan 20 min anoksie gevolg deur heroksigenasie of c) is gebruik 
in elektronvervoerkettingkompleks analise. Verder is die volgende ook bepaal: (i) 
ATP-produksie (HPLC), (ii) sitraat sintase aktiwiteit en hoeveelheid, gemeet as 
maatstaf van die aktiewe mitkondrieë per mg van proteïen en (iii) PDH-
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komplekuitdrukking en aktiwiteit (ELISA). Vlakke van GLUT 1, GLUT 4, PGC-1 
alpha, PPAR alpha, PKB/Akt, GSK-3, PTEN, AMPK, en PI 3 kinase is bepaal 
deur Western klad analise en “Real –time PCR” is gebruik om die uitdrukking van 
PDK 4 en FAT/CD 36 te bepaal.  
 
RESULTATE: Die bloedglukose- en serum insulinvlakke was beduidend verhoog 
in die dieetgroep na 8 weke van DIO. Die PPAR alpha, PGC-1 alpha en PDK 4 
vlakke was ook beduidend verhoog in die dieetgroep met geen beduidende 
verskil in die vlakke van enige van die ander proteïene gemeet of die vlakke van 
sitraat-sintase aktiwiteit nie. Na 16 weke van DIO het die vlakke van sitraat-
sintase, PTEN en p-PI 3 kinase beduidend verlaag en die % herstel na 
anoksie/heroksigenering (met die gebruik van palmitoiel-L-karnitien) het 
beduidend toegeneem in die dieetgroep. Geen ander mitokondriale veranderinge 
kon waargeneem word nie. Ons kon geen verandering vind in die mitokondriale 
oksidatiewe funksie tussen die twee groepe na 8 en 16 weke van DIO. Daar was 
ook geen verandering in die hoeveelheid ATP geproduseer gedurende staat 3 
respirasie.  
 
GEVOLGTREKKING: Die verhoogde bloedglukose en serum insulienvlakke, 
sowel as die toename in die HOMA indeks in die dieetgroep na 8 weke van DIO, 
dui daarop dat hierdie oorgewig diere insulienweerstandig is. „n Toename in die 
vlak van PPAR alpha en PGC-1 alpha uitdrukking dui op „n vroeë 
kompenserende effek, wat die verhoogde verbruik van vetsure fasiliteer. Dit is 
beklemtoon deur verhoogde vlakke van PDK 4. Ons kon geen beduidende verskil 
in die hoeveelheid PDH-ensiem vind nie, maar daar was wel „n beduidende 
toename in die vlak van PDH aktiwiteit in die dieetgroep na 16 weke van DIO. 
Mitokondrieë van die 16 weke DIO diere kon anoksie/heroksigenering weestaan 
en het geen wanfunksionering van die elektronvervoerketting getoon nie, ten 
spyte van „n vermindering in PI 3 kinase en PTEN aktiwiteit en die 
teenwoordigheid van insulienweerstandigheid. Mitokondriale biogenese blyk nie 
„n beduidende rol te speel in die hart se aanpassingreaksie nie, want daar was 
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geen verhoging in die sitraat-sintase aktiwiteit in beide groepe nie. Na aanluiding 
van die resultate verkry met hierdie studie, maak ons ook die gevolgtrekking dat 
die harte van rotte na 16 weke se blootstelling aan „n hoë vet omgewing, 
metabolies kon aanpas en goed funksioneer. Ons gevolgtrekking is dus dat die 
harte van diere wat lei aan vetsug en wat insulien weerstandig is die verlaaging 
in glukose metabolisme goed hanteer en metabolies aangepas het hierby. Dit is 
moontlik dat hierdie aanvanklike aanpasing wanaanpaslik kan word soos vetsug 
vorder.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 OBESITY, CARDIOVASCULAR DISEASE: A “GLOBAL EPIDEMIC” 
 
The World health organisation (WHO) estimated that within the next few years, 
dietary associated chronic non-communicable diseases such as ischaemic heart 
disease, diabetes, stroke and hypertension will be responsible for the bulk of the 
global burden of disease [Hennekens CH 2007]. Currently these global 
epidemics include obesity, diabetes and cardiovascular disease [Chopra et al. 
2002]. It is suggested that the progressive increase in the prevalence of these 
diseases can be attributed to an increase in the adoption of the so-called 
Western lifestyle which involves the over consumption of inexpensive high 
energy/caloric foods and reduced physical activity [Hossain et al. 2007].   
 
Cardiovascular disease (CVD) can be defined as a non-communicable disease 
affecting both the heart and the vasculature. The four most common types of 
heart disease are 1) coronary heart disease (which includes heart attack and 
angina), 2) stroke, 3) high blood pressure and 4) heart failure [American Heart 
Association March 18 2010, Learn and Live].  
 
The prevalence of CVD is increasing at an alarming rate to the extent where CVD 
has been labelled the leading cause of death and disability in the industrialized 
world [Katz 2000] with ischaemic heart disease (a form of coronary heart 
disease) being the leading cause of death in developed countries (WHO 2002). 
In the United States of America, cardiovascular related diseases are the leading 
cause of death surpassing cancer linked mortalities (National Center of Health 
Statistics 2002/3). Furthermore cardiovascular diseases are responsible for 41% 
of all deaths in North America with ischaemic heart disease leading all of the 
cardiovascular diseases (American Heart Association. Heart and stroke statistical 
update. Dallas, TX: American Heart Association; 2001).  
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South Africa is one of the many developing countries that have shown a similar 
progression to that of developed countries such as the USA, where the poor have 
become the most vulnerable to CVD [Reddy and Yusuf 1998] . It is therefore 
crucial to elucidate the causes and mechanisms of cardiovascular disease.  
 
In previous years, CVD was rifer in developed countries such as North America. 
However this is no longer the case as CVD has become more prevalent in 
developing countries as well.  This is mainly due to the increase in the incidence 
of overweight and obese individuals in lower income regions [Chopra et al. 2002]. 
 
Obesity is defined as a condition where the accumulation of excess body fat has 
reached the point where it may have adverse effects on an individual‟s health 
which leads to a reduction in life expectancy and/or an increase in health 
problems [Haslam et al. 2005]. According to the Centers for Disease Control and 
Prevention (CDC) the terms overweight and obese are both labels for ranges of 
weight that are greater than what is generally considered healthy for a given 
height. For adults these ranges (overweight- BMI between 25 and 29; obese – 
BMI of 30 or higher) are determined by a number called the “body mass index” 
(BMI). BMI is defined as weight in kilograms divided by height in meters squared, 
and is used because for most individuals it correlates with their amount of body 
fat [Eckel 1997]. It is important to remember that even though there is a 
correlation between BMI and the amount of body fat, BMI does not directly 
measure the amount of body fat. Therefore the definition of obesity still remains a 
controversial topic. 
 
The epidemic of obesity is no longer confined to developed countries. The 
prevalence of obesity is spreading to the developing world as well [He et al. 
2005; Gu et al. 2007; Kearney et al. 2005]. This is greatly due to dietary and 
lifestyle changes that accompany economic development [Folake et al. 2008]. 
Obesity is associated with numerous co-morbidities of which heart disease is the 
most common. The increase in the prevalence of obesity can be attributed to a 
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number of factors, however it has been suggested that environmental factors 
such as a high fat diet and reduced physical activity are probably the most likely 
culprits [Eckel 1997; Folake et al. 2008].  
 
Obesity is one of the most common risk factors associated with the development 
of heart disease and greatly increases an individual‟s probability of developing 
cardiovascular disease [McLellan 2002].  
 
A variety of risk factors associated with obesity such as hypertension, 
dyslipidemia, reductions in HDL cholesterol and impaired glucose tolerance or 
non-insulin-dependent diabetes mellitus appear to play a role in coronary heart 
disease risk [Eckel 1997]. The prevalence of insulin resistance as well as 
compensatory hyperinsulinemia is increased in obese individuals [Reaven et al. 
2004]. In addition CVD is considered to be the leading cause of death in the 
diabetic population [Duncan et al. 2007]. 
 
 However, the interaction between obesity, insulin resistance and cardiovascular 
disease remain not fully understood. To better understand these interactions, the 
mechanism of obesity-induced insulin resistance and cardiovascular 
abnormalities is reviewed in the following section.  
 
1.2 INSULIN RESISTANCE 
 
1.2.1 Overview of insulin action 
 
Insulin is a polypeptide hormone secreted by the beta cells in the islets of 
Langerhans in the pancreas. It plays an important role in the regulation of the 
metabolism of carbohydrates and fats, especially the conversion of glucose to 
glycogen, which lowers the blood glucose level. Insulin acts on insulin sensitive 
tissue such as brain, fat, muscle and liver tissue to allow the transport of glucose 
into cells [Ebeling P et al. 1998]. Insulin is released by the pancreas in response 
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to various stimuli. However the transport of insulin from the beta-cells is mainly 
determined by the plasma glucose levels and the concentrations of amino acids 
and fatty acids [Waselle et al. 2005]. 
 
Although the main role of insulin is to regulate glucose homeostasis, it is also 
involved in the regulation of a wide range of vital metabolic pathways and cellular 
functions [Saltiel et al. 2001]. A few of these vital metabolic and cellular 
processes include: glycolysis, glycogenesis, transport of ions and amino acids, 
lipid metabolism, DNA synthesis, gene transcription, mRNA turnover, protein 
synthesis and degradation as well as having a role in cellular growth and 
differentiation. A deficiency in insulin can lead to the development of type 1 
diabetes and related disorders [Gupta 1997]. 
 
1.2.2 The role of insulin in glucose homeostasis: 
 
Insulin is the main role player in the regulation of glucose homeostasis [Khan et 
al. 2002]. It is of great importance that blood glucose levels remain constant as 
persistently high blood sugar concentrations over many years can lead to the 
development of a variety of clinical complications such as retinopathy, 
nephropathy and cardiovascular disease. All of these diseases play a role in 
increasing an individual‟s chances of morbidity and mortality [Khan et al. 2002]. 
 
Insulin plays a crucial role in the uptake of glucose into cells by stimulating the 
translocation of the main glucose transporter in muscle and fat cells GLUT4, to 
the plasma membrane where it facilitates the transport of glucose into the cell 
thereby normalising the increased post-prandial glucose levels [Watson et al. 
2001]. The GLUT4 transporter relies largely on insulin stimulation for its 
translocation and this mechanism involves the activation of phosphatidylinositol 
3-kinase (PI 3 kinase) together with specific serine/threonine phosphorylation 
events [Miura et al. 2001]. The involvement of the classic insulin signalling 
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pathway and specifically PI 3 kinase in the translocation of GLUT4 transporters to 
the plasma membrane has been established [Khan et al. 2002].  
 
Another key role player in the regulation of glucose homeostasis is protein kinase 
B (PKB/Akt). Its involvement in insulin signalling and the regulation of glucose 
homeostasis have been studied extensively using knockout mouse models as 
one of the approaches. The PKBβ isoform appears to be the main isoform 
present in insulin-responsive tissues and is strongly associated with the 
maintenance of glucose homeostasis [Dummler et al. 2007]. 
 
1.2.3 The insulin signalling pathway: 
 
In order for insulin to exert its effects it has to bind to its cell-surface receptor. 
The insulin receptor consists of two alpha subunits and two beta subunits which 
are linked to form a α2β2 heterotertrametric complex [Khan et al. 2002]. Following 
the binding of insulin to the extracellular alpha subunits, a signal is transmitted 
across the plasma membrane which activates the intracellular tyrosine kinase 
domain of the beta subunit. This allows the receptor to undergo a series of 
intramolecular transphosphorylation reactions in which one beta subunit 
phosphorylates its adjoining partner on specific tyrosine residues. Once the 
insulin receptor has been activated, it phosphorylates a variety of important 
proximal substrates on tyrosine, such as members of the insulin receptor 
substrate family (IRS1/2/3/4), Shc adapter protein isoforms and single regulatory 
protein (SIRP) family members The tyrosine phosphorylation of the IRS proteins 
creates recognition sites for additional effector molecules containing Src 
homology 2 (SH2) domains e.g. the p85 regulatory subunit of the type 1A PI 3-
kinase. [Pessin et al.2000]. This regulatory subunit resides in the cytosol bound 
to a catalytic p110 subunit forming a dimer which, upon recruitment of the p85 
subunit brings the catalytic subunit, to the plasma membrane in order to catalyze 
the phosphorylation of the 3‟postition in the inositol ring of phosphoinositide (PI) 
lipids. In the case of insulin signalling this specifically involves the formation of PI 
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(3, 4, 5)- triphosphate from PI (4, 5) –biphosphate, and PI(3, 4)-biphosphate from 
PI (4)-phosphate which, in each instance, is catalyzed by the Type IA PI 3 
kinase. The phosphorylated and activated 3‟postition of these PI lipids recruits 
and activates the 3‟phosphoinositide-dependent kinase-1 (PDK-1). The 
phosphorylated PDK-1 then activates certain downstream effectors such as the 
two classes of serine/threonine kinases Akt (also known as protein kinase B) and 
protein kinase C (PKCδ/λ).  These two effectors in turn induce the translocation of 
GLUT 4 to the plasma membrane. [Khan et al. 2002].  
 
1.2.4 The pathophysiology of Insulin resistance 
 
Insulin resistance encompasses defective insulin signalling and glucose transport 
into cells [Ginsberg 2000].  Insulin resistance is strongly correlated to the 
development of heart disease as can be seen in the diabetic community where 
cardiovascular mortality has been found to be the leading cause of death and 
disability [Duncan et al. 2007]. 
 
Generally insulin resistance can be the result of a pre-receptor or post-receptor 
abnormality [McFarlane SI et al. 2001]. In this regard insulin resistance will occur 
if PI 3-kinase activation is diminished. The insulin-PI 3 kinase pathway, once 
activated plays an important role in stimulating vascular nitric oxide (NO) 
production, cardiovascular cation transport mechanisms and glucose transport in 
cardiovascular tissue as well as the conventional insulin-sensitive tissues fat, 
muscle and liver [McFarlane SI et al. 2001] .  
 
1.2.4.1 The role of insulin resistance in obesity and cardiovascular 
disease: 
 
As previously mentioned, insulin resistance generally refers to the resistance to 
the effects of insulin on particularly glucose uptake, metabolism, or storage [Khan 
et al. 2000]. Insulin resistance in obesity and type 2 diabetes is characterised by 
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reduced insulin-stimulated glucose transport and metabolism in specifically 
adipocytes and skeletal muscle [Reaven 1995]. Another functional defect that 
plays a role in insulin resistance in obesity and type 2 diabetes is impaired 
suppression of hepatic glucose output [Reaven 1995]. It is speculated that these 
defects may occur as a result of impaired insulin signalling in the respective 
target tissues. [Kahn et al. 2000] 
 
Obesity, especially visceral obesity, contributes greatly to impaired glucose 
tolerance, hyperinsulinemia, type 2 diabetes, dyslipidemia, hypertension and 
premature cardiovascular disease. In addition visceral obesity and assisting risk 
factors are closely correlated with an increased risk for the development of 
cardiovascular disease as illustrated by data obtained from the Quebec 
cardiovascular study [Tchernof et al. 1996]. This study revealed that visceral 
obesity is associated with two of the strongest independent risk factors for 
ischaemic heart disease. These two factors are fasting hyperinsulinemia and 
increased apolipoprotein B concentrations. Visceral fat cells, when compared 
with peripheral fat cells, tend to be more resistant to the metabolic effects of 
insulin and more sensitive to lipolytic hormones. As a result, the elevated release 
of free fatty acids into the portal system supplies increased substrate for hepatic 
triglyceride synthesis. This leads to increased production of apolipoprotein B, 
increases in the proportion of small dense low density lipoprotein particles, 
decreased HDL cholesterol, and increased triglycerides, all of which can act to 
impair the metabolism of insulin [McFarlane SI et al. 2001]. Additionally, the 
insulin resistant and diabetic heart is also more susceptible to impaired 
mitochondrial function which seems to play a very important role in the 
development of cardiovascular disease [Madrazo and Kelly 2008]. 
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1.3 MYOCARDIAL SUBSTRATE SELECTION AND UTILIZATION 
 
The heart consumes a tremendous amount of energy (ATP) and must therefore 
continuously produce large amounts of ATP in response to physiological 
demands and fuel delivery [Tian and Barger 2006]. Generally myocardium can 
take up and utilize a variety of substrates. Under so-called “normal” conditions 
i.e. sufficient nutrient and oxygen supply to the myocardium, the heart derives the 
most of its energy from the oxidation of fatty acids (60-70%), glucose (30-40%) 
and lactate (10%) [van den Brom et al. 2009]. The heart preferentially utilizes 
fatty acids as a substrate for energy production, as it produces more ATP per 
molecule than glucose [Wallhaus et al. 2001]. However under ischaemic 
conditions, when the supply of nutrients and oxygen to the myocardium is very 
limited, the heart switches from the oxygen consuming utilization of FAs to a 
more oxygen efficient, anaerobic energy producing process known as glycolysis. 
 
It has been shown that at the end stages of heart failure, the myocardium has low 
ATP content due to a decreased ability to generate ATP by oxidative metabolism, 
and thus is unable to effectively utilize fatty acids for the production of energy for 
contractile work [Ashrafian 2002; Dzeja et al. 2000; Katz 1993; Peyton et al. 
1982]. Under these circumstances utilizing carbon fuel for the production of ATP 
via glycolysis, instead of fatty acid and glucose oxidation, would prove to be more 
beneficial for the heart. 
 
However it is of great importance to remember that heart failure is not an isolated 
or specific disease, but rather a complex syndrome that is dependent on a 
number of things, including etiology, duration, underlying coronary artery disease 
and ischaemia, endothelial dysfunction, and the co-occurrence of disorders such 
as diabetes, hypertension, and obesity [Stanley et al. 2005]. Thus myocardial 
substrate selection and utilization will adjust accordingly to ensure the optimal 
production of energy (ATP) under any given circumstance to protect the heart.  
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Figure 1: An overview of myocardial metabolism [Zhou et al. 2005] 
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1.3.1 The role of obesity, insulin resistance and ischaemia in the change of 
myocardial substrate selection and utilization 
 
Metabolic stressors such as ischaemia and diabetes, specifically type 2 diabetes 
is accompanied by increased lipolysis and hypertriglyceridemia. Reduced insulin-
mediated myocardial glucose uptake and utilization alter myocardial substrate 
metabolism to further favour fatty acid oxidation [van den Brom et al. 2009]. The 
elevation in plasma free acid levels ensuing from obesity results in an increase in 
fatty acid oxidation, leading to the overproduction of fatty acid metabolites which 
act to interfere with insulin signalling, at the insulin receptor substrate level, 
effectively reducing the transport of glucose into the cell [Boden and Shulman 
2002]. When a cell becomes insulin resistant in response to obesity, myocardial 
substrate selection and utilization changes to favour and enhance fatty acid 
metabolism and reduce glucose metabolism due to a decrease in the availability 
of glucose as a substrate.  However this is not very beneficial or sought after 
under ischaemic conditions as the reduced oxygen levels will result in the inability 
of the cell to effectively utilize both glucose and the increasing levels of free fatty 
acids for the production of ATP. This inability of the cell to produce sufficient 
energy will have damaging effects on the myocardium i.e. it will result in the 
activation of detrimental processes such as apoptosis, necrosis and subsequent 
cell death [Gill et al. 2002].  
 
1.4 CELLULAR INJURY AND MYOCARDIAL INFARCTION 
 
Ischaemic heart disease commonly presents itself as a myocardial infarction.  A 
myocardial infarction, more commonly known as a heart attack, is primarily due 
to reduced blood supply to cardiac tissue. This is usually as a result of a coronary 
occlusion caused by the rupturing of an atherosclerotic plaque in the wall of an 
artery. 
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1.4.1 The development of infarct size 
 
Infarct size is a measure of the amount of cell death that occurred as a result of 
apoptosis, as it has been suggested that the inhibition of apoptosis during 
reperfusion could possibly play a role in a reduction in infarct size [Zhao Z et al. 
2003]. Necrosis and apoptosis represent two distinct types of cell death in 
myocardium, and has been associated with reperfusion induced myocardial injury 
after reversible coronary occlusion [Buja et al. 1998]. It has also previously been 
shown in rabbit, rat and dog models of regional ischaemia and reperfusion, that 
myocardial apoptosis is primarily triggered during reperfusion [Zhao et al. 2000; 
Gottlieb et al. 1994; Freude et al. 2000]. 
 
1.4.1.1 Apoptosis and Necrosis 
 
A myocardial infarction can induce cell death by both necrosis and apoptosis 
[Barr et al. 1994]. Necrosis is a passive process which occurs in response to 
lethal injury and involves the rupturing of the cell membrane, cell swelling, 
plasma membrane breakdown, clumping of nuclear chromatin, swelling and 
disruption of sarcoplasmic reticulum and mitochondria as well as the 
manifestation of the granular densities in the matrix of mitochondria [Maulik et al. 
1998]. The rupturing of the sarcoplasmic reticulum in necrotic cardiomyocytes 
results in calcium overloading which causes disturbances in other electrolytes 
[Jennings et al. 1964].  Whereas apoptosis is an active, highly regulated, energy-
requiring process that takes place without the rupturing of the cell membrane and 
is characterized by internucleosomal cleavage of DNA by a Ca2+ and Mg2+ 
dependent endonuclease [Maulik et al. 1998]. Additionally segregation of nuclear 
chromatin and condensation of the cytoplasm are some of the ultra structural 
features presented by apoptosis [Maulik et al. 1998].  
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1.4.1.1.1 Apoptosis in ischaemia/reperfusion 
 
Evidence exists that suggests that reperfusion of ischaemic myocardial tissue 
leads to reperfusion injury, a term used to describe a specific type of cellular 
injury [Maulik et al. 1998]. The generation of oxygen-derived free radicals, 
intracellular Ca2+ overloading and the redistribution of membrane phospholipids 
are all features associated with reperfusion injury and hallmarks of apoptosis  
[Richter 1993; Greenlund et al. 1995]. So it appears as though reperfusion and 
not ischaemia induces apoptosis in cardiomyocytes. Maulik et al. found no 
evidence of apoptosis in rat hearts subjected to 2 hours of ischaemia, however 
apoptosis became evident when these hearts were subjected to 15 min of 
ischaemia followed by 90 min of reperfusion [Maulik et al. 1998 (a); Maulik et al. 
1998 (b)]. 
 
The development of a myocardial infarction and the initiation of apoptosis can be 
triggered by a variety of stimuli. The overproduction of reactive oxygen species 
(ROS) by mitochondria, in response to an increase in oxidative phosphorylation, 
can act as a stimulus for the initiation of apoptosis, as ROS is capable of 
damaging certain cellular components such as proteins, lipids and DNA 
 [Halliwell et al. 1999]. 
 
It is important to note however that there are other role players in the 
development of an infarct during an ischaemic insult. The onset of intracellular 
acidosis via the inhibition of the vacuolar ATPase has been associated with the 
initiation of apoptosis in cardiac myocytes [Karwatowska-Prokopczuk et al. 1998; 
Long et al. 1998]. Elevated intracellular calcium levels observed during ischaemia 
and early reperfusion [Karmazyn and Moffat 1993]   appears to play an important 
role in ischaemia/reperfusion injury, and high mitochondrial calcium levels have 
been implicated in the induction of the permeability transition pore (PTP) 
opening, allowing the release of calcium, cytochrome c, NAD and apoptogenic 
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factors into the cytosol [Crompton et al. 1999; Di Lisa et al. 2001; Heiskanen et 
al. 1999]. 
 
1.5 CARDIOPROTECTIVE EFFECTS OF THE ACTIVATION OF PI 3-
KINASE/PKB/AKT PATHWAY DURING REPERFUSION 
 
1.5.1 PI3 kinase/PKB/Akt pathway 
 
As discussed previously insulin is a polypeptide hormone secreted by the beta 
cells in the islets of Langerhans in the pancreas and functioning in the regulation 
of the metabolism of carbohydrates and fats, especially the conversion of glucose 
to glycogen, which lowers the blood glucose level. Insulin acts on insulin 
sensitive tissues such as brain, fat, muscle and liver tissue to allow the transport 
of glucose into cells. Insulin binds to specific tyrosine kinase receptors on its 
target cells which leads to amongst others the downstream activation of the PI 3-
kinase/PKB/Akt pathway [Burgering and Coffer 1995; Franke et al. 1995]. 
PKB/Akt has been implicated as a key role player in growth factor-mediated cell 
survival and inhibition of apoptosis in response to various stimuli [Fayard et al. 
2005]. 
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Figure 2: A schematic representation of the role of the PI 3 
kinase/PKB/Akt pathway in cell survival [ref - http://www.ncbi.nlm.nih.gov/] 
 
The PI 3-kinase/PKB/Akt pathway is one of the survival pathways known to 
protect the heart against ischaemic damage during myocardial reperfusion 
[Hausenloy and Yellon 2004; Yellon and Baxter 1999]. PKB/Akt is not only 
involved in the direct and indirect negative regulation of apoptosis but PKB/Akt 
also plays a crucial role in the translocation and recruitment of GLUT 4-
containing vesicles to the membrane [Le Roith and Zick. 2001] for insertion in 
order to facilitate glucose uptake and utilization which plays a critical part in 
compensating for the increase in energy expenditure and decrease in its energy 
(ATP) producing capacity experienced during ischaemia.  
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Figure 3: Schematic representation of PKB/Akt activation 
 [Hanada et al. 2004] 
 
1.5.1.1 Activation of PKB/Akt: 
 
PKB/Akt is activated by receptor tyrosine kinases such as insulin and Insulin-like 
growth factor I (IGF-I). It has been shown that activation of PKB/Akt by these 
ligands is blocked by the PI 3 kinase inhibitors wortmannin and LY294002 thus 
implicating PI 3 kinase as one of the key role players in the activation of PKB/Akt 
[Franke et al. 1995, Burgering and Coffer 1995, Cross et al. 1995, Kohn et al. 
1995, Chan et al. 1999, Chan et al. 2003]. Phosphorylation of the threonine308 
(Thr308) and serine473 (Ser473) sites located on PKB/Akt is essential for its 
phosphorylation and subsequent activation [Alessi et al. 1996]. The Thr308 and 
Ser473 sites are phosphorylated by a Thr308 kinase, pyruvate dehydrogenase 
kinase 1 (PDK 1) [Alessi et al. 1997; Stephens et al. 1998], and a Ser473 kinase, 
which may be integrin-linked kinase (ILK) 1 [DelcomMenne et al. 1998]. 
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1.5.1.2 The role of PKB/Akt in the metabolism 
 
Glycogen synthase kinase-3 (GSK-3) is a physiological substrate for PKB/Akt 
and phosphorylates and inactivates glycogen synthase in response to insulin 
stimulation [Burgering and Coffer 1995]. PKB/Akt phosphorylates and inactivates 
both isoforms of GSK-3 (alpha and beta) in a PI 3 kinase-dependent manner 
[Hanada et al. 2004]. PKB/Akt in addition to inactivating GSK-3 is also 
responsible for the phosphorylation and activation of phosphodiesterase 3B 
(PDE3B), contributing to the regulation of the intracellular level of cAMP and 
cGMP in response to insulin [Kitamura et al. 1999], and a cardiac-specific isoform 
of 6-phosphofructo-2-kinase (6-PF2-K) resulting in the activation of this enzyme 
and the promotion of glycolysis 
[Gold 2003]. 
 
1.5.1.3 The role of PKB/Akt in the regulation of apoptosis 
 
Bcl-2/Bcl-X antagonist (BAD) is a member of the Bcl-2 family of proteins. BAD 
inhibits the anti-apoptotic potential of Bcl-2 and Bcl-X by binding to them 
[Downward 1999]. However when BAD is phosphorylated by PKB/Akt it does not 
demonstrate proapoptotic activity but rather promotes cell survival by forming 
complexes with other proteins. When phosphorylated, BAD is released from the 
Bcl-2/Bcl-X complex that is localized on the mitochondrial membrane and instead 
forms a complex with 14-3-3 [del Paso et al. 1997, Datta et al. 1997].  
 
PKB/Akt also interacts with and phosphorylates a cytosolic protein, 
phosphoprotein enriched in diabetes/astrocytes-15 (PED/PEA-15) in a PI 3 
kinase-dependent manner. This protein exhibits anti-apoptotic potential by 
inhibiting caspase 3 activity downstream of the death domain-containing 
receptors, Fas and tumour necrosis factor (TNF)-receptor family members 
[Trencia et al. 2003].  
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In addition PKB/Akt can phosphorylate caspase 9 in a Ras-dependent manner. 
Caspase 9 acts as an initiator as well as an effector of apoptosis [Donepudi and 
Grutter 2002], and phosphorylation of this protein results in the inhibition of 
cytochrome c-induced cleavage of this pro-caspase 9 which is required for the 
enzymatic action of caspase 9 [Hanada et al. 2004].  
 
1.5.1.3.1 Transcription factors involved in regulating apoptosis 
 
PKB/Akt has been shown to regulate apoptosis through transcription factors that 
are responsible for the activation of both pro and anti-apoptotic genes [Hanada et 
al. 2004]. 
 
A role for PKB/Akt in the regulation of the Forkhead (FH or FoxO) family of 
transcription factors was first identified by findings from the genetic analysis of C. 
elegans [Paradis et al. 1998, Paradis et al.1999]. The phosphorylation sites for 
PKB/Akt are highly conserved among FH isoforms and are phosphorylated 
directly by PKB/Akt [Rena et al. 1999, Biggs et al. 1999, Wolfrum et al. 2003, 
Brunet et al. 1999, Kops et al. 1999]. This phosphorylation of FH results in the 
exclusion of FH from the nucleus leading to decreased transcriptional activity 
required for promoting apoptosis. Target genes for the FH family include, 
extracellular ligands e.g. Fas ligand, TNF-related apoptosis-inducing ligand 
(TRAIL) and TNF receptor type 1 associated death domain (TRADD), and 
intracellular components for apoptosis such as bcl-2 interacting mediator of cell 
death (Bim), a propapoptotic Bcl-2 member and Bcl-6 [Burgering and Medema 
2003]. 
 
Another important transcription factor that is phosphorylated by PKB/Akt is the 
nuclear factor-κB (NFκB). NFκB is a key regulator of the imMune response and 
deregulation of its activity is implicated in the development of autoimMune 
disease and cancer [Li and Verma 2000]. NFκB is phosphorylated and activated 
in response to the phosphorylation and subsequent degradation of IκB, an 
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inhibitor of NFκB, by the Iκ B kinase (IKK) complex and PKB/Akt has been 
implicated in the direct and indirect regulation of IKK activity [Hanada et al. 2004]. 
PKB/Akt has been reported to inactivate NFκB in numerous ways including 
phosphorylating IKKα in a PI 3 kinase –dependent manner that is required for 
NFκB activation in response to TNFα (primary cytokine involved in the regulation 
of the imMune system and key regulator of apoptosis) stimulation [Ozes et al. 
1999]. A few other transcription factors have also been shown to play a role in 
the regulation of apoptosis by PKB/Akt including, cyclic AMP (cAMP)-response 
element binding protein (CREB) [Du et al. 1998], the orphan nuclear receptor 
Nurr77 [He 2002, Pekarsky et al. 2001, Masuyama et al. 2001], androgen 
receptor (AR) [Lin et al. 2001], and yes-associated protein (YAP) [Basu et al. 
2003].  
 
1.5.1.3.2 Cell cycle regulators involved in regulating apoptosis 
 
A number of cell cycle regulators have been shown to be phosphorylated by 
PKB/Akt in order to inhibit the activation of apoptosis. Murine double minute 2 
(MDM2) is one such cell cycle regulator and is a protein product of the tumour 
suppressor gene p53 [Shimizu et al. 2003]. Another is the cyclin/Cdk inhibitor 
(p21/cip1/waf1). p21 plays a crucial role in maintaining cell cycle progression and 
has been reported as a direct substrate for PKB/Akt [Coqueret 2003]. The 
phosphorylation of this protein results in the inhibition of its potential to arrest the 
cell cycle and inhibit cell growth [Zhou BP et al. 2001].  
 
 
1.6 THE REGULATORS OF THE EXPRESSION OF METABOLIC GENES IN 
CARDIOMYOCYTES 
 
Under non-ischaemic conditions, the heart produces almost all of its energy 
(>95%) via oxidative phosphorylation in the mitochondria, and the overall 
oxidative capacity of a cell greatly depends on the volume density and 
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composition of its mitochondria. As previously mentioned, mitochondria 
preferentially utilize fatty acids for ATP production, but mitochondrial substrate 
selection can be altered following an alteration in the expression of specific 
metabolic enzymes involved in these processes [Stanley et al. 2005]. Both 
nuclear and mitochondrial transcription alterations play a role in the metabolic 
changes observed in heart failure [Garnier et al. 2003]. Two regulators of the 
expression of metabolic genes can be found in cardiomyocytes. The first is 
peroxisome proliferator-activated receptor alpha (PPAR alpha) a transcription 
factor activated by the binding of endogenous Long-chain fatty acids and the 
second peroxisome proliferator-activated receptor- γ coactivator alpha (PGC-1 
alpha) a co-activator of PPAR alpha.  
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Figure 4: PPAR alpha and PGC-1 alpha are two regulators of the 
expression of metabolic genes in cardiomyocytes and are involved in the 
up and down regulation of an array of proteins involved in both FA 
oxidation and glucose oxidation. 
 
1.6.1 Peroxisome proliferator-activated receptors 
 
PPARs (peroxisome proliferator-activated receptors) are a group of nuclear 
receptor proteins that function as transcription factors regulating the expression 
of genes involved in myocardial mitochondrial fatty acid as well as glucose 
oxidation [Berger and Moller 2002; Huss and Kelly 2004]. PPARs play essential 
roles in the regulation of cellular differentiation, development and metabolism 
(carbohydrate, lipid and protein) [Berger 2005] 
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1.6.1.1 PPAR isoforms 
 
There are three isoforms of PPARs, alpha, gamMa and delta, expressed 
throughout the body (Berger and Moller 2002; Gilde et al. 2003; Huss and Kelly  
and Scarpulla 2004; Lehman and Kelly 2002). All PPARs heterodimerize with the 
retinoid X receptor (RXR-) and bind to specific regions of DNA of target genes 
called peroxisome proliferators hormone response elements, generally present in 
the promoter region of the gene of interest. PPAR alpha is highly expressed in 
tissues that have high rates of fatty acid oxidation such as the heart, liver, brown 
fat and kidney [Stanley et al. 2005]. Activation of PPAR alpha in the heart results 
in an increase in the expression of fatty acid oxidation enzymes as well as an 
increase in the rate of fatty acid oxidation in cardiomyocytes [Gilde et al. 2003] as 
it has been shown that PPAR-alpha knockout mice have decreased expression 
of fatty acid oxidation enzymes and suppressed fatty acid oxidation [Campbell et 
al. 2002].  
 
1.6.2 Peroxisome proliferator-activated receptor-γ coactivator  
(PGC)-1 alpha  
 
Peroxisome proliferator-activated receptor-γ coactivator (PGC)-1 alpha is a 
member of a family of transcription coativators that plays a central role in the 
regulation of cellular energy metabolism. PGC-1 alpha has also been implicated 
as a key role player in a process known as mitochondrial biogenesis, as it has 
been shown that the overexpression of PGC-1 alpha in the heart results in an 
increase in the mRNA of numerous mitochondrial genes [Lehman et al. 2000]. 
 
1.6.3 The role of PPAR alpha and PGC-1 alpha in cardiomyocytes 
 
Mitochondrial enzymes involved in cardiac energy metabolism are encoded by 
both nuclear and mitochondrial genes [Kelly and Scarpulla 2004]. This includes 
all of the enzymes involved in β-oxidation and the TCA cycle, most of the 
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electron transport subunits [Anderson et al. 1981], and mitochondrial number. 
These two sets of genes are tightly regulated in order to determine the overall 
cardiac oxidative capacity [Huss and Kelly 2005]. 
 
1.6.3.1 Transcriptional regulation of cardiac mitochondrial biogenesis 
and respiratory function 
 
The PGC-1 family of transcriptional coactivators are involved in the regulation of 
mitochondrial metabolism and biogenesis. PGC-1 alpha was the first member to 
be discovered through its functional interaction with the nuclear receptor PPAR 
gamMa in brown adipose tissue (BAT) [Puigserver et al. 1998], and has two 
related coactivators PGC-1 beta (PERC) and PGC-1-related coactivator (PRC) 
[Andersson and Scarpulla 2001, Lin et al. 2002, Kressler et al. 2002]. PRC is 
ubiquitously expressed and coactivates transcription factors involved in 
mitochondrial biogenesis [Andersson and Scarpulla 2001, Savagner et al. 2003]. 
PGC-1 alpha and PGC-1 beta are both preferentially expressed in tissues with a 
high oxidative capacity such as the heart where they provide critical regulatory 
functions with regard to mitochondrial functional capacity [Puigserver et al. 1998, 
Lin et al. 2002, Wu et al. 1999, Kamei et al. 2003, St-Pierre et al. 2003]. PGC-1 
alpha is distinct from the other PGC-1 family members because of its broad 
responsiveness to developmental alterations in energy metabolism and 
physiological and pathological signals at the level of expression and 
transactivation [Huss and Kelly 2005]. This is evident in the heart at birth as the 
expression of PGC-1 alpha increases in response to an increase in cardiac 
oxidative capacity and a perinatal shift from reliance on glucose metabolism to 
FA oxidation for energy [Lehman et al. 2000]. PGC-1 alpha can be induced by 
certain physiological stimuli, such as cold exposure, fasting and exercise, that 
increase ATP demand and stimulate mitochondrial oxidation [Puigserver et al. 
1998, Lehman et al. 2000, Baar et al. 2002,  Wu et al. 2002, Goto et al. 2000]. In 
the heart specifically activation of PGC-1 alpha increases cardiac mitochondrial 
oxidative capacity and in cardiac myocytes in culture, PGC-1 alpha has been 
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shown to increase mitochondrial number as well as upregulate the expression of 
mitochondrial enzymes and increase the rates of FA oxidation and coupled 
respiration [Lehman et al. 2000, Huss et al. 2004]. More specifically PGC-1 alpha 
activates the expression of nuclear respiratory factor-1 (NRF-1) and NRF-2 and 
is responsible for the direct coactivation of NRF-1 on its target gene promoters 
[Wu et al. 1999 (b)]. NRF-1 and NRF-2 are responsible for the regulation of the 
expression of mitochondrial transcription factor A (Tfam), which is a nuclear-
encoded transcription factor that binds to the regulatory sites on mitochondrial 
DNA and is essential for replication, maintenance, and transcription of the 
mitochondrial genome [Fisher et al. 1992, Garesse et al 2001, Larsson et al 
1998]. Additionally, NRF-1 and NRF-2 also regulate the expression of nuclear 
genes encoding respiratory chain subunits and other proteins essential for 
mitochondrial function [Scarpulla 2002, Virbasius et al. 1993].  
 
1.6.3.2 The role of PGC-1 alpha in the activation of PPAR alpha 
 
PGC-1 alpha is not only involved in regulating mitochondrial biogenesis and 
function at the transcriptional level but is also involved in the regulation of genes 
involved in the cellular uptake and mitochondrial oxidation of FAs by direct 
coactivation of PPARs as well as estrogen-related receptors (ERRs) [Vega et al. 
2000, Dressel et al. 2003, Huss et al. 2002, Schreiber et al. 2003].  
As previously mentioned PPARs are FA-activated members of the nuclear 
receptors superfamily of transcription factors and serve as central regulators of 
cardiac FA metabolism [Huss and Kelly 2005]. The isoforms PPAR alpha and 
PPAR beta are the primary regulators of FA metabolism in the heart and function 
by binding as obligate heterodimers with the RXR alpha and recruiting 
coactivators, including PGC-1 alpha, in response to direct binding and activation 
by FAs and their derivatives. PPAR alpha is responsible for the regulation of 
almost every step of cardiac FA utilization [Desvergne and Wahli 1999], which 
has been shown in studies where PPAR alpha –null mice have reduced cardiac 
expression of genes that are involved in the cellular uptake, mitochondrial 
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transport, and mitochondrial oxidation of FAs [Lee et al. 1995, Djouadi et al. 
1999]. It has also been shown that the uptake of myocardial FAs and oxidation 
rates are decreased in these mice, whereas glucose oxidation rates are 
increased [Campbell et al. 2002] and that PPAR alpha serves a homeostatic 
function during physiological and dietary stressors [Kersten et al. 1999, Leone et 
al. 1999].  
 
1.6.3.3 Peturbations in PGC-1/PPAR signalling in the insulin resistant 
and diabetic heart 
 
The diabetic cardiomyopathy that develops in the context of insulin resistance 
and diabetes is associated with increased cardiac reliance on FAs as the primary 
energy substrate [Wall and Lopaschuk 1989, Saddik et al. 1994, Belke et al. 
2000, Neitzel et al. 2003]. This phenomenon of enhanced FA oxidation and 
diminished glucose oxidation is linked to the combined effects of myocyte insulin 
resistance and high-circulating free FAs [Huss and Kelly 2005]. It has been found 
that the expression as well as the activity of PPAR alpha, PGC-1 alpha and the 
enzymes involved in mitochondrial FA oxidation are induced in insulin-deficient 
and insulin-resistant forms of diabetes in mouse models [Finck et al. 2003, Finck 
et al. 2002]. Although the direct mechanism involved in the activation of PPAR 
alpha signalling in the diabetic heart is unknown it has been suggested that the 
increase in the cellular import of FAs is most likely the culprit, serving as ligands 
for this nuclear receptor [Huss and Kelly 2005]. Other studies have however 
shown a reduction in the level of transcription by PPAR alpha in diabetic 
myocardium [Depre et al. 2000, Young et al. 2001], but this could be due to 
temporal-dependent regulatory events during the progression of diabetic 
myocardial disease.  
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1.6.3.4 Myocardial fuel shifts and heart failure in the insulin resistant 
and diabetic heart 
 
As previously described, the insulin resistant and diabetic heart is characterized 
by an increase in the FA oxidation rates, possibly as a result of the chronic 
activation of the PPAR alpha gene regulatory pathway [Huss and Kelly 2005]. 
Studies using mice with a cardiac-specific overexpression of PPAR alpha (MHC-
PPAR alpha mice) exhibit increased expression of PPAR alpha target genes 
involved in cellular FA import and peroxisomal and mitochondrial FA oxidation, 
concurrent with lipid accumulation and increased FA oxidation rates [Finck et al. 
2002, Hopkins et al. 2003 (a)], while myocardial glucose uptake and oxidation 
rates are reciprocally decreased suggesting that the chronic increased reliance 
on FAs for energy in the diabetic heart leads to pathological signatures that 
match the metabolic phenotype of the diabetic heart and that a primary drive on 
the PPAR alpha gene regulatory pathway triggers cross-talk suppression of 
glucose utilization pathways [Huss and Kelly 2005].  
 
These two regulators of the expression of metabolic genes in cardiomyocytes 
therefore play an important role in the up-regulation of the expression of an array 
of proteins involved in fatty acid metabolism, some of which include, fatty acid-
binding protein (FABP), pyruvate dehydrogenase kinase 4 (PDK4), acetyl-CoA 
carboxylase (ACC), Malonyl-CoAdecarboxylase (MCD) as well as mitochondrial 
biogenesis. They are also responsible for the down-regulation of the expression 
of an array of proteins involved in glucose metabolism some of which include 
glucose transporters 1 (GLUT 1) and 4 (GLUT 4) and glycogen synthase kinase 
3 (GSK-3).  
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Figure 5: Dynamic regulation of myocardial energy metabolism by 
developmental, dietary, and pathophysiological changes [Huss and Kelly 
2005].  
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1.7 PROTEINS IMPLICATED IN CARDIOMYOCYTE METABOLISM 
 
 
Figure 6: Overview of the major energy producing pathways – Glucose 
oxidation and Fatty acid oxidation [Ussher et al. 2006] 
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1.7.1 Glucose metabolism 
 
1.7.1.1 Glucose transporters 
 
Glucose is removed from the blood by a family of facilitative transporters also 
known as GLUTs. These transporters catalyze the transport of glucose down its 
concentration gradient into primarily striated muscle and adipose tissue. There 
are twelve known glucose transporter isoforms. These GLUT isoforms can be 
categorised into three classes: (1) Class I comprises GLUT 1-4, (2) Class II 
comprises GLUT 6, 8, 10 and 12 and (3) Class III comprises GLUT 5, 7, 9 and 11 
[Uldry and Thorens 2004].   
 
1.7.1.1.1 Glucose transporter 1 
 
Glucose transporter 1 (GLUT 1) is a ubiquitously and constitutively expressed 
membrane spanning protein [Khan and Pessin 2002]. GLUT 1 transporters are 
insulin-independent glucose transporters, functioning mainly as regulators of 
basal glucose transport in cardiac myocytes [Kodde et al. 2007]. GLUT 1 
transporters are expressed in different levels in almost every kind of tissue but 
expressed in high levels in especially human erythrocytes and endothelial cells 
lining the blood vessels of the brain [Maher et al. 1994]. GLUT 1 with the help of 
GLUT 3, another glucose transporter primarily expressed in neurons facilitate the 
transport of glucose across the blood-brain barrier and into neurons. [Watson and 
Pessin 2001].  
The transport of glucose by GLUT 1 has been described as an alternating 
conformer model in which the transporter has mutually exclusive binding sites 
located on the extracellular and on the intracellular face of the transporter. The 
binding of glucose to the extracellular/ import site induces the transporter to 
switch to the opposite conformation allowing glucose to be transported across the 
plasma membrane and into the cell [Uldry and Thorens 2004]. GLUT 1 in addition 
to transporting glucose, with a Km of ~3mM, also transports galactose, mannose 
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and glucosamine [Uldry et al. 2002]. GLUT 1 is sensitive to several inhibitors and 
the transport activity of this glucose transporter can be inhibited by the 
intracellular binding of cytochalasin B and forskolin (diterpene toxin) [Baldwin and 
Lienhard 1989, Morris et al. 1991] and the extracellular binding of HgCl2, 
phloretin, phlorizin and 4,6-O-ethylidene-D-glucose [Mueckler et al. 1994].  
 
1.7.1.1.2 Glucose transporter 4 
 
Glucose transporter 4 (GLUT 4) is the main glucose transporter whose 
translocation is reliant on insulin stimulation and is predominantly found in 
striated muscle (heart tissue), skeletal muscle and adipose tissue. Under basal 
conditions, GLUT 4 transporters are sequestered into vesicles in the interior of 
the cell. Post-prandially, as blood glucose levels rise, the released insulin 
activates a series of intracellular signalling cascades which results in the 
translocation of GLUT 4 to the plasma membrane. This process is completely 
reversible and, as circulating insulin levels reduce, so these glucose transporters 
are removed from the plasma membrane by a process known as endocytosis 
and recycled back to their intracellular storage compartments. [Watson and 
Pessin 2001] 
 
60 
PKB/Akt has been implicated in regulating the translocation of GLUT 4-containing 
vesicles to the plasma membrane, however PKB/Akt may not be the only 
downstream kinase involved in this regulation [Le Roith and Zick 2000]. Protein 
kinase C isoforms δ (zeta) and λ (lambda) are also activated by PI 3-kinase and 
PDK-1 (phosphatidylinositol dependent kinase -1) and is also involved in the 
regulation of GLUT 4 translocation [Czech and Corvera 
1999]
 
Figure 7: Insulin-stimulated translocation of GLUT 4-containing vesicles 
to the plasma membrane to facilitate the transport of glucose into the cell 
[http://student.biology.arizona.edu/honors2003/group05/bg.html] 
 
1.7.1.2 Pyruvate dehydrogenase complex (PDC) 
 
The PDC is an intramitochondrial enzyme complex [Steinbeck et al. 1986] and is 
regulated by a phosphorylation/dephosphorylation cycle that is catalyzed by 
specific pyruvate dehydrogenase kinases (PDKs) and pyruvate dehydrogenase 
phosphatases (PDPs) [Harris et al. 2001]. The pyruvate dehydrogenase complex 
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is composed of three enzymes: E1 (pyruvate dehydrogenase), E2 
(dihydrolipoamide acetyltransferase) and E3 (dihydrolipoamide dehydrogenase) 
[Sugden et al. 1995].  PDC plays a very important role in the glucose oxidation 
pathway by catalyzing the irreversible decarboxylation of pyruvate to acetyl-CoA 
[SchumMer et al. 2008]. The products, acetyl-CoA and NADH, of this 
decarboxlation reaction inhibits PDC activity directly as well as by increasing 
PDK activity [Roche et al. 2001].   
 
 
 
Figure 8: Regulation of the PDH complex - is tightly regulated by PDH 
kinases (PDK 4 specifically in the heart) and PDH phosphatases allowing it to 
switch between an inactive/phosphorylated and an active/unphosphorylated 
state. This switch between the inactive and active state is promoted by high 
ratios of AcCoA, CoASH, NADH:NAD, ATP:ADP and sudden demands upon the 
cell, signalled by Ca2+ respectively 
[http://www.bmb.leeds.ac.uk/illingworth/metabol/2120lec3.htm] 
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1.7.1.3 Pyruvate dehydrogenase kinase 4 (PDK-4) 
 
Pyruvate dehydrogenase kinase (PDK) 4 is one of the four isoforms of pyruvate 
dehydrogenase kinases and is the predominant form of PDKs in the heart and its 
expression is rapidly induced by peroxisome proliferator activated receptor-alpha 
ligands [Bowker-Kinley et al. 1998; Harris RA et al. 2001]. PDK-4 is responsible 
for the phosphorylation and inactivation of the pyruvate dehydrogenase (PDH), a 
multienzyme complex located in the mitochondrial matrix responsible for the 
conversion of pyruvate (the end-product of glycolyis) to acetyl-CoA and NADH, 
which enters the citric acid cycle and the electron transport chain respectively for 
the production of ATP. The activity of pyruvate dehydrogenase is regulated by 
specific pyruvate dehydrogenase kinases (PDKs) and pyruvate dehydrogenase 
phosphatases.  
 
PDK 4 activity is inhibited by NAD+, CoA, ADP and pyruvate and stimulated by 
NADH, acetyl-CoA and ATP. In obesity, PDK-4 activity is increased in response 
to elevated plasma fatty acid levels as an increase in fatty acid β-oxidation 
results in an increase in PDK-4‟s stimulants (NADH and Acetyl-CoA) [Stanley et 
al. 2005].  
 
The resulting decrease in the activity of pyruvate dehydrogenase leads to an 
increase in the conversion of pyruvate to lactate and eventually to acidosis, which 
can be very detrimental to the heart.  
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Figure 9: An overview of the role of key proteins such as PPAR alpha, 
PDK 4 and PDC in obesity (i.e. in response to increased plasma free FAs) 
[An and Rodrigues 2006]. 
 
1.7.1.4 Phosphoinositide- 3 kinase (PI3K) 
 
Phosphoinositide 3-kinase plays a key role in the regulation of cell growth and 
survival, and based on evidence from extensive in vivo and in vitro studies  
PI3 kinase has also been implicated as a key regulator of cardiac hypertrophy 
and cell survival and growth [Oudit et al. 2008; Oudit et al. 2004; Alloatti et al. 
2004]. There are three classes of PI 3 kinases [Stephens et al. 1993].  
Class I PI3 kinases are heterodimeric enzymes composed of a regulatory subunit 
p85 and a catalytic subunit p110 [Oudit et al. 2004].  
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PI3 kinase activation by specific insulin receptor substrates leads to the 
phosphorylation of the phosphatidyl-inositol PtdIns (4,5)P2 (PIP2) to the 
secondary messenger PtdIns (3,4,5)P3 (PIP3). PIP3 in turn recruits and activates 
PDK-1 (phosphotidylinositol dependent kinase 1) which leads to the 
phosphorylation and activation of PKB/Akt.  It has been demonstrated that 
PKB/Akt has the ability to phosphorylate multiple targets, some of which lead to 
the activation of pro-survival substrates, such as the prosurvival kinase (RISK) 
pathways [Hausenloy and Yellon 2004] and the inhibition of specific pro-apoptotic 
effectors [Mocanu et al. 2006].  
 
1.7.1.5 Phosphatase and tensin homolog on chromosome ten (PTEN) 
 
PTEN also known as the phosphatase and tensin homologue on chromosome 10 
is a dual protein and lipid phosphatase, which negatively regulates the PI3 kinase 
pathway [Hlobilkova et al. 2003]. It is ubiquitously expressed in all cells and its 
activity is reflected by its cellular level [Mocanu et al. 2006]. PTEN 
dephosphorylates PIP3 back into PIP2, thereby promoting the inhibition of pro-
survival substrates and activating specific pro-apoptotic effectors. 
 
 
Not much is known about the role of PTEN in the pathology of the ischaemic 
myocardium; however it has been shown that PTEN down regulation may be one 
of the mechanisms responsible for ischaemic preconditioning protection in 
normal hearts [Cai and Semenza 2005]. Levels of PTEN are increased in diabetic 
rat hearts [Mocanu et al. 2006] and it has been demonstrated that the inhibition of 
PTEN in diabetic mice can be associated with a decrease in blood glucose 
[Butler et al. 2002].  
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Figure 10:  Schematic representation of the negative regulation of PI 3 
kinase through the dephosphorylation of PIP3 to PIP2 by PTEN [Sansel et 
al. 2004] 
 
1.7.1.6 Glycogen synthase kinase 3 (GSK-3) 
 
Glycogen synthase kinase 3 is a serine/threonine protein kinase involved in the 
phosphorylation and inactivation of glycogen synthase [Doble et al. 2003]. GSK-3 
has two isoforms namely GSK-3α and GSK-3β both of which are expressed in 
the heart [Crackower et al. 2002, Doble and Woodgett 2003, Toker and Cantley 
1997, Gross et al. 2004]. Phosphorylation of GSK-3β by PKB/Akt results in the 
inhibition of GSK-3 β which leads to improved cell survival and hypertrophy 
[Doble and Woodgett 2003, Haq et al. 2000, Antos et al. 2002]. Activation of 
PKB/Akt by insulin results in the phosphorylation and inactivation of GSK-3, 
rendering it incapable of inhibiting glycogen synthase activity thereby stimulating 
glycogen synthesis [Cross et al. 1995]. GSK-3 also inactivates the protein 
synthesis eukaryotic initiation factor (eIF)-2B (the guanine nucleotide exchange 
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factor) by phosphorylation. Insulin-mediated activation of PKB/Akt reverses these 
processes, thereby enhancing protein synthesis [Welsh and Proud. 1993].  
 
 
 
Figure 11: The regulation of GSK-3 by the insulin signal-transduction 
pathway – The binding of insulin to its cell-surface receptor triggers the 
recruitment and activation of PI 3-kinase. At the plasma membrane PI 3-kinase 
stimulates the formation of PIP3, which triggers the co-locatization of PDK 1 and 
PKB/Akt, allowing PDK 1 to activate PKB/Akt. Upon activation, PKB 
phosphorylates and inactivates GSK-3, resulting in the dephosphorylation of 
glycogen synthase and eIF2B, two substrates of GSK-3 that control the rates of 
glycogen metabolism and protein synthesis respectively [Patel et al. 2004] 
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1.7.2 Fatty acid metabolism 
 
 
 
Figure 12: An overview of the key role players involved in FA oxidation 
[An and Rodrigues 2006]. 
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1.7.2.1 Fatty acid translocase/CD 36 (FAT/CD36) 
 
Under normal/physiological conditions the heart predominantly utilizes long-chain 
fatty acids for the production of ATP [Glatz et al. 1995; Van der Vusse et al. 
1992]. However, before these Long-chain fatty acids can be oxidized it has to be 
transported across the sarcolemma and into the cardiomyocytes via a protein-
mediated transport system [Luiken et al. 1997; Luiken et al. 1999].  
 
Several transport proteins are involved in this process but the exact molecular 
mechanism of their action is not yet fully understood [Bonen et al. 2002]. One of 
these transport proteins is the 88 kDa FAT/CD36 protein [Brinkmann et al. 2002]. 
FAT/CD36, just like the glucose transporter GLUT 4 is present both at the 
sarcolemma and in intracellular storage compartments [Glatz et al. 2001]. Long-
chain fatty acid uptake was significantly inhibited when using the FAT/CD36 
blocker sulfo-N-succinimidyl oleate (SSO) [Coort et al. 2002] which demonstrates 
the involvement of FAT/CD36 in the transport of long-chain fatty acids into the 
cell. Insulin has been implicated in the translocation of FAT/CD36 to the 
sarcolemma of cardiac myocytes. Furthermore, Coort et al. 2007 was able to 
demonstrate that an increased AMPK activity in cardio myocytes is involved in 
the translocation of FAT/CD36 from its intracellular storage compartments to the 
sarcolemma [Luiken et al. 2003]. PPAR alpha is a member of the nuclear 
receptor superfamily and functions as a ligand activated transcription factor 
[Francis et al. 2003 (a)]. PPAR alpha is highly expressed in the heart [Francis et 
al. 2003] and FAT/CD36 is one of its target genes [Carley and Severson 2005]. 
Fatty acids act as endogenous ligands for cardiac PPAR alpha, therefore in 
obese and diabetic hearts, the increase in fatty acids/ligands for this transcription 
factor leads to an increase in PPAR alpha expression and the transcription of its 
target genes such as FAT/CD36 [Barger et al. 2000; Finck 2004, Carley and 
Severson 2005]. 
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1.7.2.2  Carnitine palmitoyl transferase-1 (CPT-1) 
 
CPT-1 is an important membrane protein located in the outer mitochondrial 
membrane [Woldegiorgis et al. 2000]. CPT-1 is involved in the conversion of 
long-chain fatty acyl-CoA to acylcarnitines, which facilitates the transport of long-
chain fatty acids from the cytosol to the mitochondrial matrix for β-oxidation 
[Bieber 1988, McGarry et al. 1989]. CPT-1 also catalyzes the rate-limiting step in 
fatty acid-oxidation and is tightly regulated by Malonyl-CoA[Woldegiorgis et al. 
2000].  Two isoforms of CPT-1 are expressed in mammalian tissues; a liver 
isoform (L-CPT1) and a heart/muscle isoform (M-CPT-1) [Woldegiorgis et al. 
2000]. The heart expresses both the liver and the M-CPT-1 isoforms [Adams et 
al. 1998, Zhu et al. 1997).  The L- and M-CPT1 genes are subject to 
transcriptional activation by PPAR alpha in response to high levels of long-chain 
fatty acids thereby enhancing fatty acid oxidation, and making long-chain fatty 
acids regulators of their own metabolism [Brandt et al. 1998].  
 
1.7.2.3 5’ Adenosine monophosphate – activated protein kinase 
(AMPK) 
 
AMP-activated protein kinase is a heterotrimeric complex composed of catalytic 
α-subunits and regulatory β- and γ-subunits and plays a pivotal role in regulating 
energy balance at the cellular and whole-body level [Hardie 2008]. AMPK 
activation occurs through phosphorylation of threonine 172 in the catalytic 
domain by one or more upstream AMPK kinases, one such AMPKK is the 
recently discovered LKB 1 [Woods et al. 2003]. 
 
AMPK is considered to be a “metabolic master switch” [Winder et al. 1999; 
Hardie and Hawley 2001] and is rapidly activated during myocardial ischaemia 
[Kudo et al. 1995; Kudo et al. 1996; Marsin et al. 2000] and could potentially be 
an essential mediator in controlling fatty acid and glucose metabolism during and 
following ischaemia by shutting down energy consuming processes and 
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facilitating energy producing processes [Hardie and Hawley 2001]. During 
ischaemia the increased breakdown of ATP results in an increase in AMP levels 
[Hardie and Hawley 2001]. As the AMP/ATP ratio increase so does the AMPK 
activity [Kudo et al. 1995; Kudo et al. 1996]. 
 
Myocardial ischaemia incites the heart to rapidly adapt to the restricted oxygen 
supply and nutrients by switching from aerobic to anaerobic metabolism to 
maintain the level of ATP necessary for contractile function, ion channel activity 
and cell integrity [Sambandam and Lopaschuk 2003].   
 
Figure 13: AMPK as a cellular energy sensor that controls metabolic 
pathways [http://www.card.ucl.ac.be/BasicResearchP1.html] 
 
1.7.2.3.1 AMPK and glucose uptake during ischaemia 
 
Following an ischaemic insult the heart becomes less efficient at converting 
energy into contractile function [Lopaschuk and Stanley 1997], because FA 
oxidation dominates over glucose oxidation as the main source of mitochondrial 
metabolism and overall ATP production. However, during ischaemia the uptake 
of glucose as well as glycolysis increase which results in an increase in proton 
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production [Dennis et al. 1991, Hochachka and MomMsen 1983] as a 
consequence of the uncoupling of glycolysis and glucose oxidation. Energy 
dedicated to contractile function is then used to re-establish ionic homeostasis.  
 
The preferential use of FAs a source of fuel during and following ischaemia is the 
result of two factors including 1) an increase in the levels of circulating FAs 
[Mueller et al. 1978, Lopaschuk et al. 1994] and 2) decreased control of FA 
metabolism as a result of subcellular changes in the heart [Kudo et al. 1995, 
Kudo et al. 1996, Saddik et al. 1993]. One such important subcellular change is 
the decrease in malonyl-CoA (an endogenous inhibitor of FA oxidation) levels 
which leads to the dysregulation of FA oxidation [Kudo et al. 1995, Kudo et al. 
1996, Saddik et al. 1993, Dyck et al. 1998]. Malonyl-CoA levels are regulated by 
the rates of two enzymes, acetyl-CoA carboxylase (ACC) and malonyl-CoA 
decarboxylase (MCD). ACC and MCD are involved in the synthesis and 
degradation of malonyl-CoA respectively and the activity of these two enzymes 
are controlled by AMPK which is activated during ischaemia. This activation of 
AMPK results in a decrease in malonyl-CoA levels which subsequently leads to a 
loss in mitochondrial FA uptake control [Hopkins et al. 2003 (b)].  
 
1.7.2.3.1.1 Control of FA oxidation by malonyl-CoA 
 
Malonyl-CoA regulates FA oxidation by the inhibition of CPT-1, which leads to a 
reduction in mitochondrial FA oxidation rates. As previously mentioned, malonyl-
CoA is synthesized from acetyl-CoA by ACC [Saddik et al. 1993 
, Bianchi et al. 1990], and degraded through decarboxylation by the MCD 
enzyme [Dyck et al. 1998, Dyck et al. 2000]. Malonyl-CoA plays an important 
metabolic signalling role in the heart and therefore it has to be degraded rapidly 
with a half-life of only 1.25 min [Reszko et al. 2001].  
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Figure 14: Schematic representation of the inhibition of CPT-1 by 
malonyl-CoA [Hopkins et al. 2003 (b)] 
 
1.7.2.3.1.1.1 Synthesis of malonyl-CoA 
 
Two isoforms of ACC, ACC alpha and ACC beta, are present in the heart [Abu-
Elheiga et al. 1997] of which ACC beta is directly involved in the regulation of FA 
oxidation [Abu-Elheiga et al. 2000], allowing the synthesis of malonyl-CoA to 
occur in close physical proximity to CPT-1 to enable the direct inhibition of this 
mitochondrial transporter. Additionally, evidence from various studies suggests 
that ACC beta is an important regulator of FA oxidation in cardiac myocytes 
[Makinde et al. 1997], and that it plays an important role in the regulation of FA 
oxidation rates in the heart.  
 
1.7.2.3.1.1.2 Degradation of malonyl-CoA 
 
MCD is the enzyme responsible for the degradation of malonyl-CoA to acetyl-
CoA and an increase in the activity of this enzyme has been shown to decrease 
malonyl-CoA levels and increase FA oxidation in the reperfused ischaemic heart 
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[Dyck et al. 1998]. Studies using a streptozotocin-induced diabetic rat heart 
model have shown an increase in the activity and expression of MCD [Sakamoto 
et al. 2000], as well as an increase in mRNA expression during high-fat feeding, 
fasting and streptozotocin-induced diabetes [Young et al. 2001]. This suggests a 
role for MCD in altering energy metabolism. 
 
1.7.2.3.1.2 The role of AMPK in the regulation of malonyl-CoA levels 
 
As previously mentioned the activity of ACC and MCD in the heart are both under 
phosphorylation control of AMPK [Hopkins et al. 2002 (b)], making AMPK a key 
role player in the regulation of malonyl-CoA levels as well as FA oxidation in the 
heart. 
 
AMPK is activated by the AMP/ATP ratio and the creatine/phosphocreatine ratio 
[Ponticos et al. 1998]. However, in the heart, the activity of AMPK can be altered 
under conditions where significant alterations in the AMP/ATP ratio do not occur 
[Beauloye et al. 2001], such as in the case of where insulin has been shown to 
inhibit AMPK kinase (a kinase known to phosphorylate and significantly increase 
the activity of AMPK [Hardie and Carling 1997]) activity in isolated perfused 
hearts, specifically under conditions where the AMP/ATP and 
creatine/phosphocreatine ratios did not change [Beauloye et al. 2001]. 
 
In the heart AMPK acts as a metabolic sensor which is activated during metabolic 
stress such as hypoxia when ATP levels are low [Hopkins et al. 2003 (b)]. AMPK 
is also a key role player in the regulation of FA oxidation in myocardium by 
increasing the rates of FA oxidation when ATP levels are low, and decreasing FA 
oxidation when ATP levels are high. This regulation is accomplished through the 
modulation of ACC and MCD [Hopkins et al. 2003 (b)].  
Various studies have shown a close correlation between the phosphorylation and 
inactivation of ACC which leads to decreased synthesis of malonyl-CoA, relieving 
the inhibition of CPT-1-mediated uptake of mitochondrial FAs [Park et al. 2002].  
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Studies have shown that AMPK activation in cardiac cells results in the 
translocation of overexpressed MCD from the cytoplasm to the mitochondria 
[Hopkins et al. 2003 (b)]. Whether or not AMPK is responsible for the direct 
phosphorylation of cardiac MCD remains unclear [Hopkins et al. 2003 (b)].  
 
 
 
Figure 15: AMPK activation and subsequent phosphorylation of ACC and 
possibly MCD leads to an alteration in the levels of malonyl-CoA and 
subsequently increases FA oxidation [Hopkins et al. 2003 (b)] 
 
1.7.2.3.1.3 The role of AMPK during ischaemia/reperfusion 
 
AMPK is responsible for the increase in both FA oxidation and glycolysis during 
ischaemia/reperfusion to increase the production of energy in response to the 
high energy demand under these conditions [Hopkins et al. 2003 (b)]. Ischaemia 
has been shown to cause a rapid increase in the phosphorylation and activity of 
AMPK [Kudo et al. 1995]. Increased phosphorylation and activation of AMPK 
may increase myocyte glucose utilization by increasing the uptake of glucose, 
through increased translation of GLUT 4 to the sarcolemMa of the myocyte 
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[Russel RR 3rd et al. 1999], or by increasing the rate of glycolysis through 
increased phosphorylation and activation of phosphofructokinase-2 which 
produces fructose 2, 6-bisphosphate (potent activator of glycolysis) [Marsin et al. 
2000]. Additionally AMPK also increase FA oxidation rates [Hopkins et al. 2003 
(b)]. The activation of AMPK during ischaemia leads to the preferential use of 
FAs as a substrate of residual oxidative metabolism, and an increase in the 
production of lactate and protons (deleterious glycolytic by-products) as a result 
of FA-inhibition of glucose oxidation [Hopkins et al. 2003 (b)]. 
 
Increased AMPK activity continues during reperfusion of the myocardium [Kudo 
et al. 1995], continuing the exposure to high levels of circulating FAs. The rates 
of FA oxidation recovers [Lerch et al. 1992] and glycolytic rates remain elevated 
[McVeigh and Lopaschuk 1990]. This results in a greater uncoupling between 
glycolysis and glucose oxidation and subsequent proton production [Liu et al. 
1996], and reduced recovery of the pH level post reperfusion [Liu et al. 2002]. 
ACC activity is reduced and malonyl-CoA levels reduced [Kudo et al. 1995]. The 
reduction in malonyl-CoA levels could explain the high rates of FA oxidation that 
occurs during reperfusion [Kudo et al. 1995]. The levels of MCD however are 
maintained [Dyck et al. 1998], resulting in a net decrease in steady-state malonyl-
CoA levels. During this time the balance between the synthesis of malonyl-CoA 
and its degradation is shifted towards its breakdown which may relieve the 
inhibition of CPT-1. This increase in the transport of FAs into the mitochondria 
together with higher levels of circulating FAs may lead to enhanced ischaemic 
damage of the myocardium [Hopkins et al. 2003 (b)].  
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Figure 16: Activation of AMPK in response to ischaemia which leads to 
ischaemia/reperfusion damage through increased FA oxidation and 
glycolysis and reduced glucose oxidation [Hopkins et al. 2003 (b)] 
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1.8 THE ROLE OF MITOCHONDRIA IN MYOCARDIUM 
 
1.8.1 Mitochondrial ATP production 
 
Mitochondria are membrane-enclosed organelles distributed throughout the 
cytosol of most eukaryotic cells [Henze and Martin 2003]. In muscle cells the 
mitochondria are situated underneath the cell membrane and in between the 
myofibrils [Palmer et al. 1977]. Mitochondria are responsible for producing the 
majority of the energy (ATP) in the cell [Bindoff 2003]. The process of aerobic 
respiration occurs in the mitochondria in the presence of oxygen and relies on 
processes such as pyruvate decarboxylation, the citric acid cycle, the electron 
transport chain and oxidative phosphorylation for the production of ATP.  
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1.8.1.1 Pyruvate decarboxylation: 
 
Pyruvate decarboxylation is a reaction, generally catalyzed by the pyruvate 
dehydrogenase complex, which uses pyruvate to form acetyl-CoA, releasing 
NADH and carbon dioxide via decarboxylation. This reaction takes place in the 
mitochondrial matrix and usually acts as an important link between the anaerobic 
metabolic pathway, glycolysis, and the aerobic citric acid cycle [Molecular Biology 
of the Cell, 4th Edition, Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter 
P 2002]. 
 
 
 
 
 
Figure 17: Schematic representation of the conversion of pyruvate to 
acetyl-CoA by the pyruvate dehydrogenase complex enzyme 
[http://comMons.wikimedia.org] 
 
1.8.1.2 Citric acid cycle 
 
The citric acid cycle is composed of a series of enzyme-catalysed chemical 
reactions that occur in the matrix of the mitochondrion. Acetyl-CoA produced 
from pyruvate decarboxylation is used by the citric acid cycle to ultimately 
produce two molecules of ATP, six molecules of NADH, two molecules of QH2 
(Q-electron acceptor), and four molecules of CO2 per glucose molecule. [Wolfe 
and Farook 1990] 
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Figure 18: Schematic representation of the citric acid cycle 
[http://www.uic.edu/classes/phar/phar332/Clinical_Cases/vitamin%20cases/
thiamin/thiamin_pyrophosphate.htm] 
 
1.8.1.3 Oxidative phosphorylation: 
 
The electron transport chain is the site of oxidative phosphorylation, where the 
NADH and succinate generated in the citric acid cycle are oxidized [Schultz and 
Chan 2001]. The energy released from this process is used to power the ATP 
synthase enzyme. During oxidative phosphorylation, electrons are transferred 
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from electron donors to electron acceptors such as oxygen. These reactions are 
called redox reactions [Matthews 1985].  
 
The electron transport chain is a series of five protein complexes linked together 
in the mitochondrial inner membrane. The energy released by the flow of 
electrons through the chain, or redox reactions, is used to create a proton 
gradient across the inner mitochondrial membrane in a process called 
chemiosmosis [Mitchell and Moyle 1967]. Chemiosmosis creates potential energy 
in the form of a pH gradient and an electrical potential across this membrane. 
The flow of protons back across the membrane down this gradient through the 
ATP synthase enzyme uses this energy to generate ATP [Mitchell and Moyle 
1967].  
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Figure 19: This schematic represents an overview of mitochondrial 
oxidative phosphorylation. The phosphorylation of ADP to ATP at complex V 
(ATP synthase) is driven by a proton gradient across the inner mitochondrial 
membrane. The oxidation of carbon substrate in the TCA cycle generates 
reducing equivalents that subsequently provide electron flow to the electron 
transport system. Electrons are transferred from NADH through complex I (NADH 
dehydrogenase) and oxidation of succinate by complex II (succinate 
dehydrogenase). Electron flow from other sources such as electron transferring 
flavoprotein is not shown. 
[http://flaggedrevs.labs.wikimedia.org/wiki/Oxidative_phosphorylation] 
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1.8.1.4 Electron transport chain complexes I-IV: 
 
 
 
Figure 20: Overview of the electron transport chain. 
[http://www.elmhurst.edu/~chm/vchembook/596electransport.html]  
 
1.8.1.4.1 The production of ATP by the electron transport chain 
 
NADH and another hydrogen ion enter complex I and passes along the 2 
hydrogen ions to the interspace in the mitochondria. These 2 hydrogen ions act 
as a proton pump and are utilized by ATP synthetase to produce an ATP for 
every two hydrogen ions produced. Complex 3 and 4 also act in this manner, 
producing 2 hydrogen ions each thus generating 3 molecules of ATP for every 
use of the complete electron transport chain. In addition NADH passes along 2 
electrons to first FMN, then to an iron-sulfur protein FeS and finally to coenzyme 
Q. The net effects of these reactions are to regenerate coenzyme NAD+ which is 
ready to react with metabolites in the citric acid cycle creating a cycling effect.  
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Coenzyme Q picks up an additional 3 hydrogen ions in order to produce CoQH2. 
Coenzyme Q is also lipid soluble and can therefore move through the membrane 
to come into contact with enzyme complex III. Coenzyme QH2 carrying an extra 2 
electrons and 2 hydrogen ions now starts a cascade of events through enzyme 
complex III (cytochrome reductase bc).  
 
Cytochromes contain a heme structure which contains iron ions. These iron ions, 
initially present in the +3 state, are changed to the +2 state by the addition of an 
electron. The Coenzyme QH2 passes along the 2 electrons first to cytochrome b1 
heme, then b2 heme, then to an iron-sulfur protein, then to cytochrome c1 and 
finally cytochrome c, while releasing another two hydrogen ions into the 
mitochondrial interspace. Cytochrome c is also capable of moving through the 
lipid membrane layer and diffusing toward complex IV which is also known as 
cytochrome c oxidase. This complex is responsible for the removal of two 
electrons from two molecules of cytochrome c and transferring them to molecular 
oxygen, producing a molecule of water while simultaneously moving two protons 
across the membrane producing a proton gradient. These final hydrogen ions are 
then used together with the previously released four hydrogen ions to ultimately 
produce ATP. The final step towards the production of ATP is the ATP 
synthetase enzyme which can be found at numerous locations in the bilayer 
membrane of the mitochondria. The proton gradient created by the efflux of 
hydrogen ions into the mitochondrial interspace is used by the FoF1 ATP 
synthase complex to produce ATP via oxidative phosphorylation. The Fo 
component of the ATP synthase acts as an ion channel for return of protons back 
to the mitochondrial matrix, during which free energy, produced during the 
generation of the oxidized forms of the electron carriers NAD+ and Q, is 
released. This free energy is then used to drive ATP synthesis by the F1 
component of the ATP synthase.  
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1.8.1.4.1.1 Complex I: 
 
Complex I, also known as NADH reductase contains a coenzyme flavin 
mononucleotide (FMN) which is similar to FAD. NADH is a metabolite produced 
by the citric acid cycle which interacts with the complex I enzyme of the electron 
transport chain. Complex I is responsible for removing 2 electrons from NADH 
and transferring them to a lipid-soluble carrier known as ubiquinone (Q). This 
reduced product, ubiquinol (QH) is free to diffuse within the membrane while 
Complex I is simultaneously moving 4 protons across the membrane, producing 
a proton gradient. Complex I produces a lot of harmful free radicals due to the 
high incidence of premature electron leakage to oxygen. 
 
1.8.1.4.1.2 Complex II: 
 
Complex II, unlike complex I, is not a proton pump but a succinate 
dehydrogenase enzyme which funnels additional electrons in to the quinine pool 
(Q) by removing electrons from succinate and transferring them via FAD to Q. 
Other electron donors such as fatty acids also funnel electrons into Q via FAD, 
also without creating a proton gradient.  
 
1.8.1.4.1.3 Complex III: 
 
Complex III or the cytochrome bc1 complex is responsible for the stepwise 
removal of two electrons from QH2 at the Qo site and the sequential transfer of 
these two electrons to two molecules of cytochrome c. Cytochrome c is a water-
soluble electron carrier located within the intermembrane space. Complex III like 
complex I may leak electrons to oxygen resulting in the formation of reactive 
oxygen species.  
 
Therefore although oxidative phosphorylation plays a crucial role in the 
production of ATP, which is a vital part of the metabolism, it also produces large 
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amounts of reactive oxygen species such as superoxide and hydrogen peroxide 
which may cause damage to cells and can ultimately lead to cell death [Gill et al. 
2002].  
 
 Although mitochondria are the main site for ATP generation in most tissues, 
mitochondria also participate in a number of alternative activities such as 
intracellular calcium regulation, thermogenesis and the control of apoptosis 
[Kowaltowski 2000].  
 
1.8.2 Pathophysiology associated with impaired mitochondrial ATP 
production 
 
Mitochondria play a critical role in cellular function. They are responsible for the 
majority of the ATP production of the cell and play a number of other important 
roles such as the regulation of energy expenditure, apoptosis signaling, and the 
production of reactive oxygen species [Lanza et al. 2009]. Mitochondria are the 
main site for the generation of reactive oxygen species (ROS), such as hydrogen 
peroxide, with complex III of the electron transport chain being the dominant site 
for its production [Chen et al. 2007]. 
 
Cardiac ischaemia causes damage to the mitochondrial electron transport chain 
[Lesnefsky et al. 2001 (b); Lesnefsky et al. 1997; Rouslin 1983], and 
mitochondrial dysfunction contributes to myocardial injury during ischaemia and 
reperfusion [Lesnefsky et al. 2001 (b); Chen et al. 2007]. 
 
An alteration in mitochondrial function has also been implicated as the underlying 
cause of several pathological states, such as mitochondrial disorders [Gardner 
and Boles 2005], cardiac dysfuction [Lesnefksy et al. 2001 (b)] as well as the 
aging process [Lanza et al. 2009]. Therefore it is of great importance to 
understand their involvement in these disorders. The implementation of direct 
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measurements of mitochondrial function and oxidative capacity of isolated 
mitochondria will provide valuable information in the pursuit to this understanding.   
 
A lot of controversy exists surrounding the relationship between insulin resistance 
and mitochondrial function. To elucidate this relationship Asmann and his 
colleagues investigated this relationship and found that insulin is a key regulator 
of mitochondrial function and impaired insulin signalling is a potential mechanism 
by which mitochondrial dysfunction manifests in insulin resistant individuals 
[Asmann et al. 2006]. Furthermore it was demonstrated that insulin stimulates 
mitochondrial ATP production rates in healthy controls but not in insulin resistant 
individuals [Stump et al. 2003]. 
 
1.9 CARDIOPROTECTION  
 
Type 2 diabetes mellitus is closely correlated with the malfunctioning of the 
intracellular insulin signalling pathway [Kondo and Kahn 2004]. It has been 
demonstrated that the PI3 kinase/Akt pathway, plays an important role in 
cardioprotection when activated during ischeamia/repefusion [Hausenloy and 
Yellon 2004]. 
 
1.9.1 The role of mitochondrial biogenesis in cardioprotection 
 
Recent evidence suggests that impaired mitochondrial function plays an 
immense role in the underlying pathogenesis of insulin resistance and Type II 
diabetes and that PGC-1 alpha, being the key regulator of mitochondrial 
biogenesis, could play an important role in restoring mitochondrial function and 
oxidative capacity through its activation [Wu and Boss 2007]. As previously 
mentioned, mitochondrial biogenesis is PPAR alpha-PGC-1 alpha driven. A 
recent study conducted by Duncan et al. [2007] looked at mitochondria in the 
hearts of insulin resistant UCP-DTA (insulin-resistant uncoupling protein-diptheria 
toxin A ) transgenic mice, a murine model of metabolic syndrome, and found that 
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there was a significant increase in the levels of expression of both PPAR-alpha 
and PGC-1 alpha as well as a significant increase in the number of mitochondria 
present between the myofibrils, mitochondrial volume density, mitochondrial DNA 
content, and the expression of nuclear and mitochondrial genes involved in 
energy transducing and ATP synthetic pathways. It is likely that this mitochondrial 
biogenic response that occurs during the initial stages of insulin resistance, 
before the onset of Type II Diabetes, is aimed at increasing the heart‟s capacity 
for ATP generation as a potentially adaptive response, but will eventually become 
maladaptive with the onset of diabetes. These findings provide important insight 
into the role metabolic derangements play in the pathogenesis of heart failure 
due to common diseases such as atherosclerosis, hypertension and diabetes. 
And that PPARs or, perhaps more likely, downstream metabolic pathways could 
act as possible targets for new therapeutics aimed at normalizing cardiac fuel 
metabolism in order to prevent or possibly treat cardiovascular diseases 
[Madrazo and Kelly 2008]. 
 
Mitochondrial biogenesis is a complex process that involves the synthesis, 
import, and incorporation of protein as well as lipids to the existing mitochondrial 
reticulum, and the replication of the mitochondrial DNA [Hock and Kralli. 2009].  
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1.10 ADAPTIVE AND MALADAPTIVE RESPONSES OF THE HEART: 
 
 
Figure 21: Metabolic adaptation and maladaptation of the heart. Various 
stimuli can result in rapid alterations in fatty acid and glucose metabolites within 
the cardiomyocytes. These metabolites then act as essential signalling molecules 
for the adaptation process. However, if the intensity of the stimulus is too great, 
or multiple stimuli act simultaneously (e.g. pressure overload plus diabetes), 
pathological accumulation of metabolites results in metabolic maladaptation 
[Young et al. 2001]. 
 
The heart‟s response to alterations in its environment is an intricate network of 
interconnecting signal transduction cascades [Sugden and Clerk 1998]. The 
concept of alterations in the metabolic flux within the cell aimed at creating 
essential signals for the adaptation of the heart to disorders such as diabetes that 
cause metabolic dysregulation has been considered in the liver and is novel for 
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the heart [Young et al. 2001]. These changes in metabolic flux occur rapidly and 
are brought about by the same signal transduction cascades allegedly involved in 
the adaptation of the heart to changes in its environment [Young et al. 2001]. 
Certain key metabolic proteins such as PI3 kinase, Ca2+ and PKC, which play a 
crucial role in cardiac adaptation, are involved in the regulation of  metabolism in 
the heart as well [Doenst and Taegtmeyer 1999; Cohen 1979] suggesting that 
metabolic remodelling could possibly be involved in cardiac adaption. 
 
1.10.1  Metabolic adaptation 
 
Metabolic adaptation appears to be fundamental for the preservation of 
contractile function of the heart under different stresses such as diabetes. 
Metabolic adaptation involves the alteration of contractile protein gene 
expression to the re-expression of fetal genes with concomitant adult gene 
repression [Young et al. 2001]. The aim of this kind of adaptation is to 
compensate for the reduction in cardiac output by inducing the expression of fetal 
genes and facilitating substrate switching in order to maintain cardiac output 
[Young et al. 2001].  
 
The fetal heart primarily utilizes glucose for the production of energy however at 
birth the increase in dietary fatty acid intake results in an increase in the 
availability of fatty acids as a fuel substrate and in the activation of genes 
involved in fatty acid metabolism. PPAR alpha is partly responsible for the 
mediation of this effect [Brown et al. 1995; Makinde et al. 1998].  
 
1.10.1.1 Metabolic adaptation in the diabetic heart 
 
The diabetic heart relies a great deal on fatty acids for the production of energy. 
However fatty acids inhibit glucose oxidation through the pyruvate 
dehydrogenase complex. PDC is the enzyme responsible for catalyzing the 
committed step for glucose oxidation. In the diabetic heart, increased 
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mitochondrial acetyl-CoA levels as well as phosphorylation by PDK 4 inhibit the 
actions of the pyruvate dehydrogenase complex [Wu et al. 1999, Randle et al. 
1978]. The increased citrate levels usually present in the diabetic heart as a 
result of increased fatty acid utilization results in the potentiation of inhibition of 
phosphofructokinase (PFK) by ATP which acts to further prevent the oxidation of 
glucose.  
 
Having said that, we have to ask the question of whether substrate switching is 
essential for the adaptation of the diabetic heart. Studies using PPAR alpha 
knockout fasted mice show that these animals develop contractile dysfunction 
and die [Leone et al. 1999]. The origin of cardiac dysfunction in this particular 
model appears to be as a result of the accumulation of lipids within 
cardiomyocytes also known as lipotoxicity [Leone et al. 1999].  This phenomenon 
suggests that the inability of the heart to respond to increased fatty acid 
availability, via the activation of PPAR alpha-regulated genes, ultimately results in 
heart failure [Young et al. 2001]. 
 
Early hyperinsulinemia, hyperglycaemia, and hyperlipidemia are all features of  
type 2 diabetes mellitus/insulin resistance and the increase in plasma 
nonesterified fatty acid levels associated with the presence of diabetes results in 
the activation of PPAR alpha which induces the expression of PPAR alpha 
regulated genes i.e. FAT, MCPT1, MCAD, LCAD, PDK 4, MCD and UCP 3 
[Gulick et al. 1994; Brandt et al. 1998; van der Lee et al. 2000; Young et al. 
2001a; Young et al. 2001b; Wu et al. 1999 (b)]. The induction of these genes 
together with increased availability of fatty acids is associated with enhanced 
utilization of fatty acids by the diabetic heart [Stanley et al. 1997]. Additionally it is 
believed that sustained elevations in the availability of glucose can inhibit fatty 
acid utilization at the level of gene expression as recent work done in islet cells 
show that exposure to glucose decreases the expression of PPAR alpha and 
several PPAR alpha regulated genes such as the above mentioned proteins 
involved in fatty acid oxidation [Roduit et al. 2000]. This phenomenon, if present 
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in the heart, could explain why PPAR alpha expression is low in the fetal and 
diabetic heart [Young et al. 2001; Lehman et al. 2000; Barger and Kelly 2000]. 
 
1.10.2  Metabolic Maladaptation 
 
Three mechanisms of metabolic maladaptations are known in the heart, they 
include lipotoxicity, glucotoxicity and a combination of the two known as 
glucolipotoxicity [Young et al. 2001].  
 
1.10.2.1 Lipotoxicity 
 
As previously mentioned the diabetic heart is exposed to a hyperglycaemic and 
hyperlipidemic environment to which initially it adapts by increasing the 
expression of fatty acid oxidation proteins and increasing the heart‟s reliance on 
fatty acids as fuel. This form of compensation allows the heart to maintain cardiac 
output under the hyperglycaemic and hyperlipidemic conditions. However the 
long –term effects of such a mechanism is detrimental to the heart as the 
availability of excessive lipids and fatty acids will eventually surpass the use of 
these substrates by the heart and lead to lipid accumulation inside the 
cardiomyocytes [Young et al. 2001]. Previous studies have shown that in rat 
hearts a dramatic decrease in the expression of PPAR alpha occurs as diabetes 
progresses [Young et al. 2001]. Sustained exposure to high levels of fatty acids 
along with the limiting PPAR alpha activity present during diabetes accelerates 
lipid accumulation within the heart. This phenomenon is known as lipotoxicity 
[Zhou et al. 2000; Lee et al. 1994]. Hearts isolated from insulin-resistance ZDF 
rats show increased lipid deposition within the cardiomyocytes, increased 
ceramide levels, DNA laddering indicative of apoptosis, and contractile 
dysfunction [Zhou et al. 2000]. This additional evidence supports the notion that 
increased ceramide levels, produced from excessive lipids and fatty acids, can 
induce the accumulation of ROS, INOS (inducible nitric oxide synthase) and 
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apoptosis [Bielawska et al. 1997; Unger and Unger 2001] which may result in 
contractile dysfunction of the heart.  
 
The accumulation of glucose metabolites can be just as detrimental as the 
accumulation of excessive lipids and can lead to the development of glucose-
induced insulin resistance in skeletal muscle, liver and adipose tissue [Rossetti et 
al. 1987]. In addition decreased insulin sensitivity is a common trait in both 
glucose induced insulin resistance and the diabetic heart [Doenst et al. 2001; 
Tahiliani and McNeil 1986; Sakamoto et al. 2000].  
 
1.10.3  Mitochondrial dysfunction and insulin resistance: 
 
Metabolic changes that occur in the insulin resistant state have been shown to be 
accompanied by reduced mitochondrial oxidative activity as well as mitochondrial 
ATP synthesis, which are both indicative of reduced mitochondrial function 
[Qatanani and Lazar 2007]. Because mitochondria are the primary cellular site for 
both FA oxidation and utilization it has led to a great deal of interest in the role of 
reduced mitochondrial function. 
 
There are a variety of techniques that allow you to measure mitochondrial 
function. In our study we used 1) estimates of oxidative phosphorylation potential 
by measuring key enzymes involved in the TCA cycle, such as pyruvate 
dehydrogenase and citrate synthase, 2) active measures of mitochondrial 
function by isolating mitochondria and measuring oxygen consumption capacity 
with varying substrates e.g. glutamate, palmitoyl-L-carnitine, malate, succinate, in 
the presence or absence of pharmaceutical modifiers such as rotenone, 
succinate, oligomycin and CCCP (Carbonyl cyanide 3-chlorophenylhydrazone), 
quantifying ATP production during state 3 respiration (HPLC) and 3) key 
mitochondrial biogenesis biomarkers such as PGC-1 alpha, PPAR alpha and 
AMPK . 
 
93 
1.11 MOTIVATION FOR STUDY 
 
The Early Effects of Diet-induced Obesity on Myocardial Function in a Rat 
Model 
 
A study aimed at assessing the early effects of diet-induced obesity (DIO) on 
myocardial function in a rat model showed that after only 8 weeks of diet-induced 
obesity these obese rats were already starting to display signs of insulin 
resistance. Significant elevations in the blood glucose levels (mmol/L) (control: 
3.78 ± 0.13 vs. Diet: 4.66 ± 0.20; p=0.0034), serum insulin levels (mIU/ml) 
(control: 25.16 ± 5.21 vs. Diet: 52.58 ± 9.0; p=0.04) as well as an elevation in the 
body weight (g) (control: 358.29 ± 5.12 vs. Diet: 396.08 ± 7.07; p=0.0006) 
confirmed this. In addition these obese rats also showed significantly elevated 
plasma triglyceride, phospholipid, and lipid peroxidation levels as well as a 
significant decrease in aortic output recovery after global ischaemia  
[Huisamen et al. 2007].  
 
In contrast, these obese rats displayed a significant decrease in the infarct size 
after regional ischaemia [Huisamen et al. 2007]. This was unexpected in view of 
many studies done on obesity, insulin resistance and the subsequent 
development of a myocardial infarction with larger infarct sizes in the obese 
group when compared to their age-matched controls. For example one such 
study found that the hearts from young insulin resistant Zucker obese (ZO) rats 
developed significantly larger infarcts than their lean (ZL) counterparts (infarct 
size: 57.3 ± 3% in ZO vs. 39.2 ± 3.2% in ZL; P< 0.05) [Katakam et al. 2006].  
  
We therefore set out on a systematic investigation of signalling pathways 
involved in myocardial substrate utilization after a switch to a high caloric diet. 
We hypothesized that pathways involved in glucose utilization will be down 
regulated with concomitant up regulation of fatty acid utilization pathways leading 
to mitochondrial adaptations and eventually myocardial maladaptation.  
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1.12 AIMS 
 
Our specific aims were: 
 
1) To determine whether the expression of key proteins involved in the 
regulation of glucose and fatty acid metabolism as well as mitochondrial 
oxidative phosphorylation has changed 
 
2) To determine the oxidative phosphorylation potential of mitochondria in the 
hearts of control vs. DIO rats after 8 weeks (early) or 16 weeks (late) of 
diet 
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CHAPTER 2: METHODS 
 
2.1 Animals 
 
Age and weight matched male Wistar rats were used for this study. Rats were 
weaned at 4 weeks of age and were allowed free access to food and water. Rats 
were housed in the University of Stellenbosch Central Research Facility, with a 
12-hour artificial day-night cycle where a constant temperature of 22°C and 
humidity of 40% were maintained. Throughout the study, the revised South 
African National Standard for the care and use of laboratory animals for scientific 
purposes was followed [South African Bureau of Standards, SANS 10386, 2008]. 
Ethical clearance for all projects were obtained from the committee for ethics in 
animal research of the University of Stellenbosch.  
 
2.1.1 Study design 
 
 Upon reaching ~200g, rats were randomly assigned to either a control or a diet 
(DIO) group. Control rats were fed a standard rat chow diet while the diet group 
received a special diet i.e. standard rat chow supplemented with sucrose and 
condensed milk. Rats were fed for a period of either 8 or 16 weeks. At the 
appropriate time the rats were weighed, sacrificed and their hearts removed. A 
group of hearts were freeze clamped immediately at baseline and another group 
of hearts were used to isolate mitochondria. Freeze clamped hearts were stored 
at -80°C and were used for biochemical analysis at a later stage. A separate 
series of rats were used for each protocol (Figure 22 pg 95-96). 
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Figure 22:  (A) and (B) Study design for the respective groups after 8 and 
16 weeks of diet.  
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2.1.2 Diet 
 
The special obesity inducing diet contained standard rat chow supplemented with 
sucrose and condensed milk. This high caloric diet consisted of 33% standard rat 
chow, 33% sweetened full cream condensed milk (Clover), 7% sucrose and 27% 
water [Pickavance et al. 1999]. Obesity in this model was induced primarily by 
hyperphagia.  The food was replaced daily to avoid fermentation of wet food.  
 
Table 1: Composition of control and DIO group’s diet. 
  
Control: 
 
DIO: 
Carbohydrates: 60% 65% 
Protein: 30% 19% 
Fat: 10% 16% 
Kj/day 371±8 570±23 
 
All animals were anaesthetized by intra-peritoneal injection of Eutha-naze 
(sodium pentobarbital) (0.16 g/kg animal body mass) prior to being slaughtered.  
 
2.2 Blood glucose determination 
 
Rats were fasted overnight and blood samples were collected from the tail vein. 
A drop of the blood was placed on the absorbent film of an Accu-check 
advantage II slip (Roche Diagnostics, USA). The slip was subsequently inserted 
into an Accu-Check glucometer (Roche Diagnostics, USA) in order to determine 
blood glucose levels.  
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2.3 Measurement of serum insulin levels 
 
Non-fasting blood samples were collected from the thoracic cavity after the rats 
had been sacrificed and were stored at 4°C until analyzed. The Coat-A-Count® 
Insulin assay was used for the quantitative measurement of the serum insulin 
levels. This assay is a solid-phase 125I radioimmunoassay, in which a fixed 
amount of 125I-labeled insulin competes with the insulin, present in the blood 
sample, for binding sites on an insulin specific antibody. The insulin specific 
antibody is immobilized in the wall of the polypropylene tube and therefore, 
simply decanting the supernatant eliminates the competition and isolates the 
antibody-bound fraction of the radiolabeled insulin. Radioactivity was then 
measured by using a gamma scintillation counter (Cobra II Auto Gamma, A.D.P, 
South Africa).  
 
2.3.1 Experimental procedure 
 
All tests were done in duplicate and all assay components were brought to room 
temperature according to the manufacturer‟s instructions. Four uncoated 
polypropylene tubes were labeled: total counts (1-2) and non-specific binding (3-
4). Fourteen insulin antibody-coated tubes were labeled  
[A (maximum binding)-G]. Additionally, tubes for the controls and samples were 
also labeled.  
 
200 µl of the zero calibrator A was pipetted into the non-specific binding tube as 
well as the tube labeled A (maximum binding) and 200 µl of each remaining 
calibrator, control and sample was pipette into their respective prepared tubes.  
1.0 ml of 125I insulin was added to every tube and vortexed. Samples were then 
incubated for 18-24 hours at room temperature. After the incubation period the 
samples were decanted by placing each tube (except the total count tube) in a 
foam decanting rack and allowing the tubes to drain for approximately 3 minutes 
after which each tube was struck on absorbent paper to remove excess moisture. 
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Removal of the excess moisture ensures a more precise assay.  The radioactivity 
of each tube was then measured in a gamma counter (Cobra II Auto Gamma, 
A.D.P, South Africa) for 1 minute per tube. 
 
2.3.2 HOMA index 
 
The HOMA (homeostasis model assessment) is a noninvasive measurement 
technique for insulin sensitivity.  The product of the fasting concentrations of 
glucose (mmol/L) and insulin (mIU/mL) is divided by a constant (22.5 – if glucose 
concentration is expressed in Système International units). The HOMA 
calculation, unlike other measurement techniques for insulin sensitivity, 
compensates for fasting hyperglycemia [Quon 2001].  Results from previous 
studies indicate that HOMA is highly sensitive and specific for measuring insulin 
resistance [Keskin et al. 2005]. Additionally it is a much simpler, non-invasive, 
inexpensive, less laborious and time consuming than other measures of insulin 
sensitivity [Keskin et al. 2005].  
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2.4 Pilot study 
 
A pilot study was conducted to determine whether differences in the activation of 
PKB/Akt was responsible for smaller infarct development found in hearts of rats 
after 8 weeks of diet. 
 
2.4.1 Perfusion protocol 
 
Isolated rat hearts were excised and placed in ice cold Krebs-Henseleit buffer 
containing NaCl 119 mM, NaHCO3 24.9 mM, KCl 4.74 mM, KH2PO4 1.19 mM, 
MgSO4 0.6 mM, Na2SO4 0.59 mM, CaCl2 1.25 mM, glucose 11 mM. This buffer 
was also used as the perfusate and was kept at a pH of 7.4 and oxygenated by 
continuously gassing it with 95% oxygen/5% carbon dioxide. The perfusion 
protocol for hearts from obese animals (n=6) and hearts from control animals 
(n=6) was as follows: 30 minutes stabilization, 35 minutes regional ischaemia, 
accomplished by ligating the left anterior descending artery, and 10 minutes of 
reperfusion. The Langendorff perfusion system was used. At the end of 
reperfusion the infarcted zone was dissected out and frozen separately from the 
non-infarcted zone.  
 
 
  
  
  
 
 
Figure 23: Retrograde perfusion protocol  
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2.5 Biochemical analysis 
 
2.5.1 Infarcted vs. Non-infarcted zones 
 
Lysates were prepared from frozen tissue as described in section 2.5.2. The 
standard Bradford protein determination method [Bradford 1976] and Western 
blotting techniques were used to determine the level of expression of total and 
phosphorylated PKB/Akt in the infarcted and non-infarcted zones of all the 
perfused hearts (control n=6; diet n=6). 
 
A separate set of hearts were freeze clamped at baseline without perfusion 
(control n=6; diet n=6) and later used to determine the level of expression of the 
following proteins: 
 
 PPAR α 
 PGC-1 α 
 GLUT1 
 GLUT 4 
 GSK -3 (total and phosphorylated) 
 PI 3 kinase (total and phosphorylated) 
 PTEN (total and phosphorylated) 
 PKB/Akt (total and phosphorylated) 
 AMPK (total) 
 
2.5.2 Preparation of lysates 
 
Tissue lysates were prepared using a lysis buffer (Ph 7.4), containing  
20 mM Tris , 1 mM EGTA, 150 mM NaCl, 1 mM EDTA, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM PMSF, 
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10 μg/ml Leupeptin, 10 μg/ml  Aprotonin, 1% Triton X-100. This lysis buffer was 
used for the analysis of GLUT 1, GLUT 4, GSK-3, PI 3 kinase, PTEN and AMPK.   
 
PPAR alpha and PGC-1 alpha protein were extracted with a modified lysis buffer 
(pH 7.4), containing 20 mM Tris ,  1 mM EGTA, 150 mM NaCl, 1 mM EDTA,  
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,  
1 mM PMSF, 10 μg/ml Leupeptin, 10 μg/ml  Aprotonin, 1% Triton X-100,  
1 mM Mg Cl2.  
 
Frozen heart tissue was added to the lysis buffer and homogenized using a 
Polytron PT10 homogenizer (2 x 5 seconds setting 4). The homogenized tissue 
was then transferred to eppendorf tubes and centrifuged for 10 minutes at 4°C. 
The supernatant was transferred to clean eppendorf tubes, kept on ice and the 
protein concentration determined using the Bradford protein determination 
method. 
 
2.5.2.1 The Bradford protein determination method 
 
50 µl of the supernatant from each sample was diluted 10 x with dH20 to dilute all 
detergents that may interfere with the assay.  
 
2.5.2.1.1 Bradford procedure 
 
 Dilute the Braford reagent stock solution 1:5 and filter through 2x filter paper 
 Generate a standard curve using a bovine serum albumin (BSA) stock 
solution of known concentration 
 Pipette 5 µl of each diluted sample and add 95 µl H20 
 Add 900 µl Bradford reagent to each tube, vortex and incubate samples for at 
least 15 minutes at room temperature 
 Read the optical density at 595 nm 
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 Use the standard curve generated in excel (protein concentration on x-axis 
and OD values on the y-axis) and calculate the protein content (µg/ µl) of 
each sample 
 Use the protein concentration to dilute the samples with lysis buffer to 
equalize the protein concentration/volume  
 Add Laemli sample buffer (3:1) and boil for 5 minutes 
 Store samples at -20°C until further use in imMune blotting procedure 
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2.5.3 Immuno Blotting 
 
2.5.3.1 Separation of proteins 
 
Table 2:  Protocol for stack gel 
Reagent Stock 4% 
H2O (Millipore)  2.7 ml 
Tris-HCl (pH 6.8) 0.5 M 1.25 ml 
SDS 10% 50 µl 
Acrylamide 40% 450 µl 
APS (AmMonium persulfate) 10% 50 µl 
TEMED (Tetramethylethylenediamine) 99% 10 µl 
 
Table 3:  Protocol for separation gel 
Reagent Stock 10% 12% 
H2O (Millipore)  3.85 ml 3.35 ml 
Tris-HCl (pH 8.8) 1.5 M 2.50 ml 2.50 ml 
SDS 10% 90 µl 90 µl 
Acrylamide 40% 2.25 ml 2.7 ml 
APS  10% 50 µl 50 µl 
TEMED (Tetramethylethylenediamine) 99% 20 µl 20 µl 
 
After casting and polymerizing the gels, the samples were boiled for 5 minutes, 
microfuged for 5 minutes and equal protein concentrations loaded onto the gels. 
The tank (BioRad Protean III apparature) was then filled with running buffer 
(composition: 50 mM Tris, 384 mM Glycine, 1.0%w/v SDS) and run according to 
the protocol listed below in tables 4-10. 
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Table 4: Western blotting protocol for PPAR alpha and PGC-1 alpha 
Protein PPAR α PGC-1 α 
Size of Protein (kDa) 52 92 
% Polyacrylamide gel 12 10 
Run period (min) 10 min + 70 min 10 min + 70 min 
Blocking period (min) 120 min 120 min 
Primary antibody (µl) 20 µl in 5 ml 5% Milk (1:250) 20 µl in 5 ml 5% Milk (1:250) 
Secondary antibody (µl) 4 µl in 20 ml 5% Milk (1:5000) 4 µl in 20 ml 5% Milk (1:5000) 
Exposure time (min) 5 min 5-10 min 
 
Table 5:  Western blotting protocol for GLUT 1 and GLUT 4 
Protein GLUT 1 GLUT 4 
Size of Protein (kDa) 55 45 
% Polyacrylamide gel 12 12 
Run period (min) 10 min + 90 min 10 min + 90 min 
Blocking period (min) 90 min in 2.5% milk 90 min in 5% milk 
Primary antibody (µl) 20 µl in 5 ml 1% milk (1:250) 5 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 3 µl in 20 ml 2.5% milk (1:6667) 5 µl in 20 ml 2.5% milk (1:4000) 
Exposure time (min) 25-30 min 25-30 min 
 
Table 6:  Western blotting protocol for total and phospho GSK-3 
Protein GSK-3 Phospho GSK-3 
Size of Protein (kDa) 52 52 
% Polyacrylamide gel 12 12 
Run period (min) 10min + 70 min 10 min + 70 min 
Blocking period (min) 90 min 90 min 
Primary antibody (µl) 5 µl in 5 ml TBS tween (1:1000) 5 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 5 µl in 20 ml 5% milk (1:4000) 5 µl in 20 ml 5% milk (1:4000) 
Exposure time (min) 10-15 min 10-15 min 
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Table 7: Western blotting protocol for total and phospho PI 3 kinase 
Protein PI 3 kinase Phospho PI 3 kinase 
Size of Protein (kDa) 85 85 
% Polyacrylamide gel 12 12 
Run period (min) 10min + 70 min 10min + 70 min 
Blocking period (min) 90 min 90 min 
Primary antibody (µl) 5 µl in 5 ml TBS Tween (1:1000) 5 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 5 µl in 20 ml 5% milk (1:4000) 5 µl in 20 ml 5% milk (1:4000) 
Exposure time (min) 20-23 min 20-30 min 
 
Table 8: Western blotting protocol for total and phospho PTEN 
Protein PTEN Phospho PTEN  
Size of Protein (kDa) 54 54 
% Polyacrylamide gel 12 12 
Run period (min) 10 min + 70 min 10min + 70 min 
Blocking period (min) 120 min 120 min 
Primary antibody (µl) 5 µl in 5 ml TBS tween (1:1000) 5 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 5 µl in 20 ml 5% Milk (1:4000) 5 µl in 20 ml 5% milk (1:4000) 
Exposure time (min) 12 – 14 min 10-12 min 
 
Table 9: Western blotting protocol for total and phospho PKB/Akt 
Protein PKB/Akt Phospho PKB/Akt 
Size of Protein (kDa) 60 60 
% Polyacrylamide gel 12 12 
Run period (min) 10 min + 60 min 10min + 60 min 
Blocking period (min) 120 min 120 min 
Primary antibody (µl) 5 µl in 5 ml TBS tween (1:1000) 5 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 5 µl in 20 ml 5% Milk (1:4000) 5 µl in 20 ml 5% milk (1:4000) 
Exposure time (min) 15-20 min 15-20 min 
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Table 10: Western blotting protocol for total AMPK 
Protein Total AMPK 
Size of Protein (kDa) 62 
% Polyacrylamide gel 10 
Run period (min) 10 min + 50 min 
Blocking period (min) 120 min 
Primary antibody (µl) 11 µl in 5 ml TBS tween (1:1000) 
Secondary antibody (µl) 10 µl in 20 ml 5% Milk (1:4000) 
Exposure time (min) 5-7 min 
 
Proteins were separated by SDS PAGE (sodium dodecyl sulfate polyacrylamide 
gel electrophoresis – a control sample was loaded in the first well/lane of each 
gel and used as a reference point to normalize data) and  were transferred to a 
polyvinylidene fluoride (PVDF) membrane (ImMobilonTM P, Millipore) in a transfer 
apparatus containing transfer buffer (composition: 25.0 mM Tris-HCl pH 8.3, 192 
mM glycine, 20%v/v methanol, 0.02%w/v SDS). 5% fat free milk in Tris buffered 
saline (TBS) 0.1% Tween 20 (TBST) (composition: 200 mM Tris-HCl pH 7.6, 1.37 
M NaCl) was used to block non-specific binding sites on membranes after which 
they were washed extensively with TBST (3 x 5 minutes). The membranes were 
incubated overnight with antibodies specific for each of the proteins of interest.  
TBST was used to repeatedly wash membranes (3 x 5 min). Diluted anti-rabbit 
HRP linked secondary antibody was allowed to conjugate with immobilized 
antibody on the membrane. Membranes were then again washed thoroughly with 
TBST. Membranes were covered with ECL™ detection reagents and exposed to 
autoradiography film (Hyperfilm ECL, RPN 2103 – Amersham). This was done to 
detect light emission through a non-radioactive method (ECL™ Western-blotting). 
The films that were obtained were then analyzed with laser scanning 
densitometry (UN-SCAN-IT, Silkscience).  
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2.6 Preparation and analysis of mitochondrial function 
 
2.6.1 Preparation of mitochondria from fresh heart tissue 
 
The measurement of oxygen consumption in isolated mitochondria was 
pioneered by Britton Chance over 50 years ago and is still being used today to 
assess the function of freshly isolated mitochondria [Chance et al. 1956]. 
 
Fresh isolated rat hearts were arrested in ice cold isolation medium (pH 7.4), 
containing 0.18 M KCl (13.42g/L), 0.01 M EDTA (3.72g/L), cut into pieces,  
washed repeatedly with isolation medium to remove as much blood as possible, 
and put on ice. The tissue was then homogenized with a Polytron PT10 
homogenizer (2 x 4 seconds on setting 4) on ice and  centrifuged for 10 min at 
4°C at 2 500 rpm (755 x g) in a Sorvall SS34 rotor.  The resultant supernatants 
were centrifuged at 12 500 rpm (18 800 x g) to obtain a mitochondrial pellet 
which was finally suspended in 0.5 ml isolation medium using a glass Teflon 
Potter Elvehjem homogenizer. For each of the mitochondrial experiments, a 50 µl 
mitochondrial aliquot was allowed to precipitate in 1.0 ml 10% TCA 
(trichloroacetic acid) overnight or for 30 minutes at 4ºC for protein determination  
 
2.6.1.1 Lowry’s protein determination method 
 
The Lowry protein determination method [Lowry et al.1951]. Was used to 
determine the protein content of the 50 µl aliquot of mitochondria that was 
precipitated in 10% TCA.  
 
2.6.1.1.1 Sample preparation 
 
The precipitated samples were centrifuged for 15 minutes at 2 500 rpm (755 x g), 
and the supernatant removed. 500 µl 1N NaOH was added to the pellet and 
vortexed. The samples were then heated in a water bath at 70°C for 
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approximately 10 minutes (or until the solution turned clear) in order to dissolve 
the proteins. To this mixture 500 µl dH20 was added and vortexed. The sample 
was now ready for protein determination. 
 
2.6.1.1.2 Procedure 
 
50 μl of the prepared protein sample was added to lucham-tubes in duplicate. 
Separate tubes were set aside and an albumin stock solution of known 
concentration was used to generate a standard curve (0.5 N NaOH was used as 
a blank). 1.0 ml NaK-Tartrate-CuSO4 (composition: 2% NaK-Tartrate, 1% 
CuSO4.5H2O, 2% Na2CO3) was added to all tubes with 10-30 second time 
intervals, vortexing after each addition. After 10 minutes had elapsed (measured 
from the first addition) 100 μl Folin Ciocalteu‟s reagent (diluted 1:3) was added at 
the same time intervals, vortexing after each addition. After at least 30 minutes 
the optical density was read at 750 nm (visible light) against the blank (0.5 
NaOH). The standard curve and OD values were then used to determine the 
protein concentration (mg/ml).  
 
2.6.2 Analysis of mitochondrial function 
 
Respiration of isolated mitochondria was measured at 25°C using a Clarke 
electrode (Hansatech Oxygraph), whereby the O2 consumption was measured in 
nmolO2/ml/min.  
 
An aliquot (volume dependent on end reaction volume) of  incubation medium pH 
7.4 (250 mM Sucrose, 10 mM Tris-HCl, 8.5 mM K2HPO4.2H2O, 50 mM 
Glutamate, 20 mM Malate) was placed into the chamber of the oxygraph. The 
chamber was then made anaerobic by adding sodium dithionite and the 
instrument calibrated to a 0 and 100% oxygen level. After calibration the 
chamber was rinsed repeatedly with dH2O to ensure that all traces of sodium 
dithionite had been removed.  
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A 0.65 ml aliquot of incubation medium was added to the chamber and allowed to 
become air saturated/equilibrate with ambient oxygen. After approximately 90 
seconds equilibration, an aliquot (50 µl) of mitochondrial suspension was added 
to the chamber and the recording allowed to run for 90-120 seconds. 50 µl ADP  
was then added and the stopper closed, sealing the chamber. Mitochondria were 
allowed to utilize all ADP to produce ATP (State 3 respiration) where after state 4 
respiration was allowed to progress for at least 2 min. 
  
 
 
Figure 24: Typical respiration graph generated by an oxygraph – (A) At the 
start of the experiment only the incubation medium is present containing either 
glutamate or palmitoyl-L-carnitine, then the mitochondria (B) are added and then 
the ADP and the chamber closed (C), the mitochondria are then able to utilize the 
substrates and oxygen to rapidly produce ATP (State 3 respiration) (D), and 
when almost all of the ADP has been converted to ATP respire at a slower rate 
(State 4 respiration) (E).  
 
 
A B C 
D 
E 
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 In a separate set of experiments palmitoyl-L-carnitine (5 mM) was also used as a 
substrate instead of glutamate. 
 
2.6.2.1 Anoxia/Reperfusion of isolated cardiac mitochondria 
 
0.60 ml incubation medium (containing either glutamate and malate or palmitoyl-
L-carnitine and malate) was added to the chamber. After approximately 90 
seconds 100 µl mitochondrial suspension was added. Subsequent to the addition 
of the mitochondria and after approximately 90 seconds equilibration, 50 µl ADP 
was added to the reaction mixture and the stopper closed. This sealed the 
chamber. After state 4 had been reached, ADP was added (injected through a 
small capillary tube in the chamber stopper using a Hamilton syringe) at a 
saturating level (100 µl of a 17.7 mM ADP solution) that maximally stimulated 
respiration in the presence of glutamate and malate. This lead to total oxygen 
depletion which made the chamber completely anoxic i.e. no oxygen was 
available for the mitochondria to use. After 20 minutes of sustained anoxia the 
mitochondria were reperfused by removing the stopper and bubbling oxygen 
through the reaction mixture. The mitochondria were allowed to regain state 3 
respiration which was recorded over 2 min of re-oxygenation. 
 In a separate set of experiments palmitoyl-L-carnitine (5 mM) with malate  
(20 mM) was also used as substrates. 
 
2.6.3 Mitochondrial electron transport chain complex analysis 
 
Mitochondrial function may be determined via different methods. One of these 
include the measuring of oxygen consumption in isolated mitochondria [Chance 
et al. 1956]. This technique allows you to measure the functional capacity of 
mitochondria as organelles and not as single enzyme complexes [Lanza et al. 
2009]. However, it is also crucial to combine measurements of maximal ATP 
production with measures of mitochondrial respiration, by using various 
substrates which will offer the opportunity to assess defects at specific levels 
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within the process of mitochondrial energy metabolism. In addition, different 
pharmacological substances may be used to determine the function of the 
individual enzyme complexes.  
 
2.6.3.1 Experimental Procedure 
 
0.68 ml of incubation medium was added to the oxygraph chamber. After 
approximately 90 seconds a 20 µl aliquot of mitochondrial suspension was 
added. Subsequent to the addition of mitochondria and after approximately 
another 90 seconds had elapsed, 50 µl ADP was added and the stopper closed. 
Thereafter pharmaceutical substances were added to the chamber (injected 
through a small capillary tube in the chamber stopper using Hamilton syringes) 
sequentially with ±120 second intervals. These substances include (listed in 
order of addition): 45 µl succinate (80 mM), 8 µl rotenone (50 µM), 5 µl 
oligomycin (5mg/1ml), and 8 µl carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) (5 mM). In a separate set of experiments palmitoyl-L-carnitine chloride 
(5 mM) and malate (20 mM) was also used as substrates. 
 
In our study we used a protocol described by Lanza et al. as an outline for the 
assessment of mitochondrial function of isolated mitochondria in vitro [Lanza et al 
2009]. This protocol involves serial additions of various substrates, inhibitors and 
uncouplers which allow for the comprehensive assessment of mitochondrial 
function in isolated mitochondria. 
 
1)  Gas phase equilibration:  
 
The first step in this protocol states the instrument be equilibrated with ambient 
oxygen.  
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2)  Baseline mitochondrial respiration: 
 
This is followed by measuring the baseline respiration which is achieved by 
adding an aliquot of the mitochondrial suspension to the chamber, closing it and 
measuring respiration in the absence of exogenous substrates.  
 
3)  Substrates glutamate and malate (State 2 respiration, complex I): 
 
A combination of glutamate and malate is then added which will reflect state-2 
respiration specific to complex I.  The substrate combination of glutamate and 
malate provides carbon sources for dehydrogenase reactions in the TCA cycle. 
These dehydrogenase reactions generate NADH which is subsequently oxidized 
by complex I [Lanza et al. 2009]. Additionally high concentrations of malate will 
result in product inhibition of the succinate dehydrogenase reaction.   
 
 ADP is added at a saturating level in order to stimulate state 3 respiration by 
complex I as much as possible in the presence of glutamate and malate.  
 
4)  Addition of succinate: 
 
Succinate provides additional electron flow through complex II. The addition of 
succinate will therefore stimulate respiration above glutamate-malate stimulated 
state 3. Complex II or succinate dehydrogenase, unlike complex I, is not a proton 
pump. Complex II consists of four protein subunits and is responsible for 
funnelling additional electrons into the quinine pool by removing electrons from 
succinate and transferring them via FAD to Q (Figure 20.6, pg. 367 Lanza et al. 
2009).  
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5)  Addition of rotenone: 
 
In addition to adding succinate, rotenone is also added to assess the functioning 
of complex II. Rotenone selectively inhibits complex I, which induces a redox shift 
that effectively inhibits all of the NADH-linked dehydrogenases in the TCA cycle. 
Therefore in the presence of rotenone, succinate selectively stimulates the flow 
of electrons through complex II.  
 
7)  Addition of Oligomycin: 
 
The addition of oligomycin serves as an indicator of the degree of uncoupled 
respiration or proton leak. It is used to induce state 4 respiration by inhibiting the 
Fo unit of the ATP synthase enzyme, blocking the proton channel and effectively 
eliminating ATP synthesis. In the absence of ADP phosphorylation the leakage of 
protons across the inner mitochondrial membrane can be attributed to residual 
oxygen consumption.  
 
8)  Addition of CCCP: 
 
CCCP induces an uncoupled state by dissipating the proton gradient across the 
inner mitochondrial membrane. 
 
In a separate set of experiments we substituted glutamate with palmitoyl-L-
carnitine, in order to assess ATP production by fatty acid β-oxidation [Lanza et al. 
2009].  
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2.6.4  QUANTIFICATION OF MITOCHONDRIAL ATP PRODUCTION 
 
2.6.4.1 Experimental procedure 
 
 For each of the ATP quantification experiments, the reaction was stopped and 
the reaction mixture (containing: incubation medium, mitochondria and ADP) 
removed directly after completion of state 3 respiration. The reaction mixture was 
then added to 6% Perchloric acid (PCA) and placed on ice for the determination 
of ATP via HPLC.  
 
 In a separate set of experiments palmitoyl-L-carnitine chloride (5 mM) and  
20 mM malate was also used as a substrate. 
 
2.6.4.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
 
2.6.4.2.1 Principle of experiment 
 
The analysis of high energy phosphates (HEPs) such as adenosine triphosphate 
(ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and 
creatine phosphate (CrP) by the reversed phase high pressure liquid 
chromatography (HPLC) technique was developed by Victor et al. 1987.  
 
We used reversed-phase HPLC which has a non-polar stationary phase and an 
aqueous polar mobile phase. Reverse phase chromatography operates on the 
principle of hydrophobic forces, which originate from the high symmetry in the 
dipolar water structure. RPC is allowing the measurement of these interactive 
forces. The binding of the analyte to the stationary phase is proportional to the 
contact surface area around the non-polar segment of the analyte molecule upon 
association with the ligand in the aqueous eluent. The structural properties of the 
analyte molecule play an important role in its retention characteristics i.e. in 
general an analyte with a larger hydrophobic surface (e.g. C-H, C-C, S-S )area 
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results in a longer retention time because it increases the  non-polar surface area 
of the molecule, which is non-interacting with the water structure. This is contrary 
to polar groups, such as –OH, -NH2, COO
- or –NH3
+ which reduce retention as 
they are well integrated into water.  
 
Column 
Packing:  LUNA C18 (2) 
Length:  250 mM 
ID:   4.6 mM 
Particle size:  5 µ 
Liquid:  Methanol: H2O (66:34) 
Supplier:  Phenomenex 
 
An On-line UV detector (210 nm) was used and the mobile phase (Buffer) was 
composed of 257 mM KH2PO4, 1.18 MM tetrabutylamMoniumphosphate (TBAP), 
12.5 % (v/v) HPLC graded methanol, pH 4.0 with H3PO4, filtered and de-gassed 
with Helium.  
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High energy phosphates were quantitated with appropriate standards (STD from 
Sigma), with known concentrations: 
ATP = 0.4535 nmol/10 µl 
ADP = 0.5853 nmol/10 µl 
AMP = 0.7200 nmol10 µl 
CrP = 0.7640 nmol/10 µl 
 
A: 
 
 
B: 
 
 
= (nmol/g wet weight) / 1000 
= (µmol/g wet weight)  
 
2.6.4.2.2 Preparation of samples for HPLC 
 
The volume of reaction mixture taken from the oxygraph incubation chamber, 
ranging from 650 µl – 700 µl,   was added to 1 ml of 6% PCA (Perchloric acid), 
and placed on ice for no longer than 30 minutes otherwise the acid will start to 
break down the ATP to precipitate.  After the 30 minute precipitation period the 
mixture was centrifuged at 4000 rpm at 4°C for 10 minutes and 1 ml of the 
supernatant removed and added to 5 µl Universal indicator (the addition of the 
Universal indicator will transform the supernatant from colourless to purple). To 
this a neutralization mixture is gradually added (5 µl at a time) until a green 
colour is reached (green represents a neutral pH of 7.0-7.). This mixture is then 
microfuged at 4000 rpm at 4°C for 3 minutes and the supernatant filtrated 
through a 0.45 µm nitrocellulose filter. These samples were then ready for ATP 
quantification by means of HPLC and stored at -80°C. 
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2.6.5  CITRATE SYNTHASE ASSAY 
 
2.6.5.1 Principle of experiment 
 
Citrate synthase is the initial enzyme of the tricarboxylic acid (TCA) cycle. It 
catalyzes the reaction of 2 carbon acetyl coenzyme A (acetyl CoA) with 4 carbon 
oxaloacetate (OAA) to form the 6 carbon citrate.  
 
 
 
Figure 25:  Citric acid cycle [http://www.uic.edu] 
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This enzyme is an exclusive marker of the mitochondrial matrix and its activity is 
measured by spectrophotometrically following the colour development of 5-thio-2-
nitrobenzoic acid (TNB). The addition of 5,5‟-Dithiobis-(2-nitrobenzoic acid) 
(DTNB) will allow the activity of the enzyme to be measured, as TNB (generated 
from DTNB) which is the overall reaction product absorbs light at 412 nm  
 
Reaction catalyzed by citrate synthase: 
 
Acetyl-CoA + Oxaloacetate → Citrate + CoA-SH + H+ + H2O 
 
Colorimetric reaction: 
 
CoA-SH + DTNB → TNB + CoA-S-S-TNB 
 
An aliquot (50 µl) of each preparation was stored at -80ºC and used to determine 
the amount of mitochondria per mg of total protein by means of the citrate 
synthase assay.  Citrate synthase assay kit (CS0720) from Sigma was used to 
determine the level of citrate synthase activity.  
 
2.6.5.2 Sample preparation 
 
For the detection of total citrate synthase activity in mitochondria, the stored 
mitochondria  (50 µl mitochonidra was stored at -80°C in KE isolation medium ) 
was suspended in CellLytic M Cell lysis reagent (Catalog Number C2978) using 
~200 µl per g of tissue.  
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Samples were prepared according to the reaction scheme in Table 11: 
 
Description Sample 1xAssay 
Buffer 
30 mM Acetyl-CoA 
Solution 
10 mM DTNB 
Solution 
10 mM OAA 
Solution Last to be 
added 
CelLytic M Sample  (10 µl) 920 µl 10 µl 10 µl 50 µl 
Citrate Synthase 
(positive control) 
Diluted solution 
 (10 µl) 90 µl 10 µl 10 µl 50 µl 
 
All of the reaction components were added except for the 10 mM OAA solution.  
 
2.6.5.3  Experimental procedure 
 
After sample preparation each assay solution was warmed to 25 ºC and placed in 
a 1 ml cuvette. The optical density (OD) measurements were then taken at a 
wavelength of 412 nm every 20 seconds for 1.5 minutes to measure the baseline 
reaction, endogenous levels of thiol or deacetylase activity. The oxaloacetate 
solution (10 mM) was then added, the sample gently mixed and the OD 
measurements taken again every 20 seconds for 1.5 minutes to measure total 
activity. Positive controls (positive for containing the enzyme citrate synthase) 
were also tested for citrate synthase activity. These OD values were then used to 
calculate the level of citrate synthase activity (umol/mgprot/min).  
 
2.6.6  PYRUVATE DEHYDROGENASE (PDH) COMBO  
(ACTIVITY + QUANTITY) MICROPLATE ASSAY 
 
We used the pyruvate dehydrogenase (PDH) Combo (Activity and Quantity) 
microplate assay kit (Catalog # MSP20) from MitoSciences. This kit contains two 
components: a PDH activity assay component (MSP 18), and a PDH quantity 
assay component (MSP 19), used for the quantitative and qualitative analysis of 
PDH.  
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2.6.6.1 Principle of MSP 18 
 
This kit is used to determine the activity of the pyruvate dehydrogenase enzyme 
in a sample. The PDH enzyme is immunocaptured within the wells of the 
microplate and the PDH activity is determined by following the reduction of NAD+ 
to NADH. This reaction is coupled to the reduction of a reporter dye to yield a 
coloured (yellow) reaction product. The concentration of the product of this 
reaction can be determined by measuring the increase in absorbance at a 
wavelength of 450nm.  
 
2.6.6.2  Experimental procedure 
 
The mitochondria were isolated, homogenized and the final pellet suspended in 
PBS (1.4 mM KH2PO4, 8.0 mM Na2HPO4, 140 mM NaCl, 2.7 mM KCl, pH 7.3). 
The protein concentrations of all samples were determined using the Lowry 
protein determination method prior to solubilisation and diluted to the specified 
concentration (~2 mg/ml). The sample was then solubilized and diluted to within 
the linear range of measurement as described below: 
 
Component Purified mitochondria at ~2 mg/ml 
Sample 
Detergent 
19 volumes 
1 volume 
Final protein concentration (mg/ml) 5.0 
 
The samples were incubated on ice (10 min) and then centrifuged for 10 min at 4 
°C at 5, 000 RCF (x g). The supernatant was carefully collected and the pellet 
discarded. 10 ml of the 20x Buffer (in kit) was added to 190 ml of deionized H2O 
to make a 1X Buffer which was used to dilute the samples to the desired 
concentrations.  
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200 µl of the diluted samples (in duplicate), as well as a positive and negative 
control, was added to the wells of the microplate and incubated for 3 hours at 
room temperature.  
 
After the 3 hour incubation period the wells were emptied and 300 µl of 1x 
Stabilizer (prepared by mixing 1 volume of thawed 5x stabilizer (in kit) with 4 
volumes of 1x Buffer) added to each well. This step was repeated and 200 µl of 
the Assay solution was added to each of the wells and the absorbance measured 
at 450 nm at room temperature for 15 minutes with 1 minute intervals. The optical 
density was then plotted vs. Time (s) and the PDH activity expressed as the initial 
rate of reaction determined from the slopes of the curves generated.  
 
2.6.6.3 Principle of MSP 19 
 
This kit can be used to determine the amount of PDH protein in a sample. The 
PDH enzyme is purified and immobilized by an anti-PDH capture antibody pre-
coated in the microplate wells. The amount of captured PDH is determined by 
adding a second anti-PDH antibody (detector) which binds to the captured PDH, 
followed by binding of an HRP conjugated goat-anti-mouse antibody that binds 
the detector anti-PDH antibody. The detector-bound HRP then changes the 
colourless HRP development solution to blue and the colour intensity 
(absorbance) is proportional to the amount of PDH captured.  
 
2.6.6.4 Experimental procedure 
 
The isolation of the mitochondria, measurement of the protein concentration, 
dilution and solubilisation of the samples as well the 10 minute incubation period 
on ice and the 10 min centrifugation step at 4°C is the same as described for 
MSP 18.  
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After collecting the supernatant all the samples were diluted to the desired 
concentration (as described above for MSP 18) using the Incubation solution 
[prepared by mixing 1 part 10x Blocking Buffer with 9 parts 1x Buffer (prepared 
by adding 15 ml of 20x Buffer to 285 ml deionised H2O)]. 200 µl of the diluted 
samples were then loaded into the microplate wells and incubated at room 
temperature for 3 hours. This was followed by 3 wash steps with 300 µl 
1xstabiliser (prepared by mixing 1 part 5x stabiliser with 4 parts 1x Buffer). 200 µl 
of 1x Detector (1 part 20x Detector Antibody + 19 parts incubation solution) was 
added to each well and incubated for 1 hour at room temperature. Two more 
wash steps were performed with 1x Buffer prior to adding 200 µl 1x HRP Label (1 
part 20x HRP label with 19 parts incubation solution) to each well and incubating 
at room temperature for 1 hour. Finally 3 washes were performed with 1x Buffer 
and 200 µl of HRP Development solution added to each well and the absorbance 
read immediately at 600 nm for 15 min with 1 min intervals. The blue colour 
development over time in each well is then examined and the initial absorbance 
reading subtracted from the final absorbance reading to determine the quantity of 
PDH in each well.  
 
2.7 QUANTITATIVE RT- PCR (REAL TIME – POLYMERASE CHAIN 
REACTION) ANALYSIS 
 
2.7.1 mRNA isolation 
 
We used the RiboPureTM Kit by AEC- Amersham (Catalog # AM 1924) to isolate 
high quality total RNA.  This kit is designed specifically for the purification of high 
quality RNA from tissue samples by combining the robust lysis/denaturant, TRI 
reagent, with glass filter purification to yield pure RNA, free of residual proteins 
and lipids.  
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2.7.1.1 Procedure 
 
Frozen heart tissue from both groups (following 8 and 16 weeks DIO) stored at 
 -80°C were homogenized in TRI reagent (1ml TRI reagent / ~100mg tissue) 
which is a monophasic solution containing phenol and guanidine thiocyanate 
which rapidly lyses cells and inactivates nucleases. The samples were then 
incubated for 5 min at room temperature and centrifuged at 12 000 x g for 10 min 
at 4°C, and the supernatant transferred to a new eppendorf tube. The next step 
was the extraction of the RNA. 200 µl of chloroform was added to 1 ml of the 
homogenate/supernatant and mixed well. After incubating the homogenate for 5 
min at room temperature it is centrifuged at 12 000 x g for 10 min at 4°C. The 
addition of chloroform results in the separation of the homogenate into aqueous 
and organic phases. RNA partitions to the aqueous phase while DNA and protein 
remain in the interphase and organic phase. 400 µl of the aqueous phase was 
then transferred to a new eppendorf tube for the final RNA purification step. 200 
µl of 100% ethanol was added to the aqueous phase, mixed immediately and 
passed through a filter cartridge. The filter was then washed twice with 500 µl of 
the wash solution and then finally the RNA was eluted with 100 µl of the elution 
buffer. The purified RNA sample was then stored at -80°C.  
 
2.7.2 TURBO DNA –free™ 
 
The TURBO DNA free kit from Ambion was used to remove all traces of DNA to 
render a completely DNA free RNA sample. 
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2.7.2.1 Procedure overview 
 
Add Dnase Digestion reagents 
1. Add 0.1 volume 10x TURBO Dnase Buffer and 1 µl TURBO Dnase to the 
purified RNA, and mix gently 
 
Incubate 
2. Incubate at 37°C for 20-30min 
 
Add Dnase inactivation reagent 
3. Add resuspended Dnase inactivation reagent (typically 0.1 volume) and 
mix well 
 
Incubate and mix 
4. Incubate 5 min at room temp mixing occasionally 
 
Centrifuge and transfer RNA 
5. Centrifuge at 10 000 x g for 1.5min and transfer the RNA to a fresh tube 
(store RNA at -80°C until further use) 
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2.7.3 Quantitation of RNA 
 
The concentration of RNA is determined by measuring the absorbance at 260 nm 
(A260) in a spectrophotometer. The reading at 260 nm allows for the calculation 
of the concentration of RNA in the sample. Before measuring the absorbance the 
extracted RNA sample was diluted [1:200 5 µl RNA + 995 µl DEPC 
(diethylpyrocarbonate) H2O] and the absorbance then measured in a 1 ml quartz 
cuvette (spectrophotometer calibrated with DEPC H2O).  The concentration of 
the RNA was then calculated according to the following formula: 
 
 
 
2.7.4 Purity of RNA 
 
The purity of the RNA sample was determined by measuring the absorbance at 
both 260 nm and 280 nm and calculating the ratio between the two (OD260 / 
OD280). This ratio gives you an indication of the purity of the RNA. Pure 
preparations of RNA will have an OD260 / OD280 ratio of 2.0. If the ratio is 
significantly less than this value, the sample has most likely been contaminated 
with protein or phenol. However this ratio is influenced considerably by Ph and 
since water (DEPC H2O) is not buffered the Ph and the resulting OD260 / OD280 
ratio can vary greatly. A lower pH results in a lower ratio and reduced sensitivity 
to protein contamination [Wilfinger et al. 1997].  
 
2.7.5 Integrity of RNA 
 
The integrity and size distribution of total RNA extracted with the RiboPure™ kit 
was checked by denaturing formaldehyde agarose gel electrophoresis and 
ethidium bromide staining.  
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2.7.6 Formaldehyde Agarose Gel Electrophoresis 
 
A formaldehyde agarose gel (1.2 % agarose) was prepared by mixing 1.2 g 
agarose with 10 ml 10x formaldehyde agarose gel buffer (200 mM 3-[N-
morpholino]propanesulfonic acid {MOPS}, 50 mM sodium acetate, 10 mM EDTA, 
pH =7.0 with 10 M NaOH), and 50 ml of  RNase-free water (DEPC H2O). This 
mixture was then heated to allow the agarose to melt. To the heated agarose an 
additional 40 ml of RNase-free water was added (to make the solution up to 100 
ml) to cool the mixture to ~65°C. 1.8 ml of 37% formaldehyde and 1 µl of a 
10mg/ml ethidium bromide stock solution was added to the cooled mixture, 
mixed thoroughly and poured onto gel support. The gel was allowed to 
equilibrate in 1x formaldehyde agarose gel running buffer (100 ml 10x 
formaldehyde agarose gel buffer, 20 ml 37% formaldehyde and 880 ml  
RNase-free water).  
 
To prepare the RNA sample for formaldehyde agarose gel electrophoresis, RNA, 
DEPC water and 5x RNA loading buffer (16 µl saturated aqueous bromophenol 
blue solution, 80 µl 500 mM EDTA, pH 8.0, 720 µl 37% formaldehyde, 2 ml 100% 
glycerol, 3084 µl formamide, 4 ml 10x formaldehyde agarose gel buffer and 
Rnase free water to 10 ml) were added in a 4:6 ratio (RNA, DEPC water: loading 
buffer) and mixed. It was then incubated for 3-5 min at 65°C, chilled on ice and 
then loaded onto the equilibrated gel. The gel was run for 2hrs (70 V, 100 mA) in 
1x formaldehyde agarose gel running buffer and the bands visualized using a UV 
box and SynGene GeneSnap version 6.07 (serial no. 
11496*9125*vacutec*mpcs) software.  
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2.7.7 cDNA synthesis 
 
High capacity cDNA reverse transcription kit with RNase inhibitor for 200 
reactions from Applied Biosystems was used (part no. 4374966) to synthesise 
cDNA from the RNA that we isolated.  
 
2.7.7.1 cDNA reaction preparation 
The kit contains reagents that, when combined, form a 2x Reverse transcription 
(RT) master mix. An equal volume of RNA sample should be added. To avoid 
RNase contamination, RNase-free reagents and consumables must be used. 
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Table 12: Instruction by the manufacturer to prepare the 2x RT master 
mix (per 20 µl reaction): 
1. Allow the kit components to thaw on ice 
2. Referring to the table below, calculate the volume of components 
needed to prepare the required number of reactions. Note: Prepare 
the RT master mix on ice 
Component: Volume (µl) / reaction kit 
With RNase inhibitor kit 
10x RT buffer 2.0 
25x Dntp Mix (100 mM) 0.8 
10x RT random primers 2.0 
MultiScribe™Reverse 
Transcriptase 
1.0 
RNase Inhibitor 1.0 
Nuclease-free water 3.2 
Total per reaction 10.0 
IMPORTANT: include additional reactions in the calculations to 
provide excess volume for the loss that occurs during reagent 
transfers. 
3. Place the 2x RT master mix on ice and mix gently. 
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Table 13: Instruction s from the manufacturer to prepare the cDNA 
Reverse Transcription reactions 
1. Pipette 10 µl of 2x RT master mix into each well of a 96-well reaction plate or 
individual tube 
2. Pipette 10 µl of RNA sample into each well, pipetting up and down two times 
to mix 
3. Seal the plates or tubes 
4. Briefly centrifuge the plate or tubes to spin down the contents and to eliminate 
any air bubbles 
5. Place the plate or tubes on ice until you are ready to load the thermal cycler 
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Table 14:  Instructions to program the thermal cycling conditions 
1. Program the thermal cycler using the conditions below. 
IMPORTANT: These conditions are optimized for use with the high-capacity 
Cdna reverse transcription kits 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min ∞ 
 
The newly synthesised cDNA was then stored at -80°C for use in the real-time 
PCR reactions.  
2.7.8 Taqman gene expression assays 
We used the PRE-DEVELOPED TAQMAN® ASSAY REAGENTS kit from 
Applied biosystems together with the Taqman gene expression assays for our 
three target genes PDK 4, FAT/CD 36 and CPT-1.  
Applied Biosystems developed the Pre-Developed TaqMan® Assay reagents 
products as a research tool for real time, in vitro relative quantitative evaluation of 
gene expression. The Pre-Developed TaqMan® Assay reagents detect the 
expression of target sequences in complementary DNA (cDNA) samples.  
 Primer sequences: 
o “Downstream” IL-1α primer for reverse transcription and amplification 
of Paw109 RNA sequence: 
5‟ –CATGTCAAATTTCACTGCTTCATTCATCC- 3‟ 
o “Upstream” IL-1α primer for amplification of Paw109 sequence: 
5‟-GTCTCTGAATCAGAAATCCTTCTATC-3‟ 
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2.7.8.1 About the kit 
This kit is used to amplify purified DNA and contains primers and probes which is 
used to detect known sequences of, in our case, cDNA. The TaqMan ® MGB 
probes contain: 
 A reporter dye linked to the 5‟ end of the probe 
 A minor groove binder (MGB) at the 3‟ end of the probe and 
 A nonfluorescent quencher (NFQ) at the 3‟ end of the probe (because the 
quencher does not fluoresce, the Applied Biosystems real-time PCR 
systems can measure reporter dye contribution more accurately. 
The 5‟ nuclease assay process takes place during PCR amplification and occurs 
in every cycle and does not interfere with the exponential accumulation of 
product. During PCR, the TaqMan MGB probe anneals specifically to a 
complementary sequence between the forward and reverse primer sites     
(Figure 24, pg. 133). When the probe is intact (Figures 25 and 26, pg. 133), the 
proximity of the reporter dye to the quencher dye results in the suppression of the 
reporter fluorescence, primarily by Förster-type energy transfer [Förster 1984; 
Lakowicz, 1983].  
The DNA polymerase cleaves only probes that are hybridized to the target   
(Figure 26, pg. 133). Cleavage separates the reporter dye from the quencher dye 
which results in increased fluorescence by the reporter. The increase in 
fluorescence occurs only if the target sequence is complementary to the probe 
and is amplified during PCR. Nonspecific amplification is not detected because of 
these requirements. Polymerization of the strand continues, but because the 3‟ 
end of the probe is blocked, no extension of the probe occurs during PCR (Figure 
27, pg 133).  
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Figure 26: Polymerization reaction 
 
Figure 27: Strand displacement 
 
Figure 28: Cleavage 
 
Figure 29: Completion of polymerization 
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This product contains sufficient control primers and probe to detect the control 
sequence. The control reagent is optimized for use with TaqMan ® Universal 
PCR master mix to perform 1000 PCR reactions (50 µl each) but does not 
contain TaqMan® Universal PCR master mix.  
 
2.7.8.2 Preparing the PCR reaction mix 
The preparation of the reaction mix used in the following tables is crucial for the 
accurate calculation of relative quantification values.  
Prepare the PCR reaction mixture for each sample in a separate microcentrifuge 
tube before aliquoting the samples to the reaction plate for thermal cycling and 
fluorescence analysis. The volume of PCR reaction mix per well must be 50 µl 
minus the volume of the cDNA sample. Load 10 ng to 1 µg of cDNA (converted 
from total RNA) per well, depending on your target of interest. The contents of 
the PCR reaction mix are as follows: 
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Table 15:  Components (Multiplex: Target + Control reactions) 
 
Concentration Volume/tube (µl) Final 
RNase-free water 20 µl – y - 
2x TaqMan® Universal PCR master mix 25 µl 1x 
20x Target primers and probe 2.5 µl 1x 
20x Control primers and probe 2.5 µl 1x 
cDNA sample y (µl) - 
Total volume 50 µl 1x 
 
Note: This reaction is optimized for TaqMan ® Universal PCR master mix. Mix 
the PCR reaction mixture and cDNA samples prior to addition to the MicroAmp® 
optical 96 well reaction plate to ensure optimal performance of your PCR 
reactions. 
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Table 16:  Setting thermal cycler conditions: 
 
Times and Temperatures 
Initial Steps Each of 40 cycles 
 Melt Anneal/extend 
Stage Hold Hold Cycle 
Temperature 50.0°C 95.0°C 95.0°C 60.0°C 
Time 2 min 10 min 15 sec 1 hour 
 
 
2.7.8.2.1 Analysis of results 
 
Our results generated from the 7900 HT thermal cycler was analyzed using 
REST 2009 software from Qiagen.  
 
2.8 Statistical analysis 
 
All data is expressed as mean ± S.E.M. Statistical significance between groups 
was assessed by two way analysis of variance (ANOVA) followed by a Bonferroni 
post-hoc test for multiple comparisons. Alternatively an unpaired Student t test 
was used to compare statistical differences between control and DIO groups. A 
p-value of less than 0.05 (p<0.05) is considered as statistically significant. 
Statistical analysis of data was performed using GraphPad Prism 5. REST 2009 
software was used for statistical analysis of relative expression of the genes of 
interest in our PCR experiments, and represented as whisker-box plots. A 
hypothesis test is used by REST 2009 software to determine whether a 
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significant difference exists between diet and controls, while taking reaction 
efficiency and reference gene normalization into account.  
 
The box area in a whisker-box plot provides additional information about the 
skew of the data distributions that would not be available simply by plotting the 
sample mean. The whisker-box plot encompasses 50% of all observations, the 
dotted line represents the sample median and the whiskers represent the outer 
50% of observations (Figure 30) [Rest 2009 Software Guide]. 
 
 
 
 
Figure 30: Whisker-box plot 
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CHAPTER 3:  RESULTS 
 
3.1 CHARACTERISTICS OF THE DIET-INDUCED OBESITY MODEL 
 
3.1.1 Body weight 
 
 
 
 
 
 
 
 
 
Figure 31: Mean weight (g) after 8 weeks of DIO (n=6 per group) 
A significant increase was found in the mean body weight (g) in the diet group 
when comparing control and DIO groups (294.8 ± 16.7 vs. 362.8 ± 6.9; p=0.0037) 
23.08% weight gained in DIO group. 
 
 
 
 
 
 
 
 
 
Figure 32: Mean weight (g) after 16 weeks of DIO (n=8 Control n=9 DIO) 
A significant increase was found in the mean body weight (g) in the diet group 
when comparing control and DIO groups (399.7 ± 11.1 vs. 468.2 ± 12.0; 
p=0.0008) 31.8% weight gained in DIO group.  
Control DIO
0
100
200
300
400 *
M
e
a
n
 w
e
ig
h
t 
(g
)
Control DIO
0
200
400
600
*
M
e
a
n
 w
e
ig
h
t 
(g
)
140 
3.1.2 Intra-peritoneal fat weight  
 
 
 
 
 
 
 
 
 
 
Figure 33: Mean intra-peritoneal fat weight (g) after 8 weeks of DIO  
(n=15 control n=19 DIO). A significant increase was found in the mean intra-
peritoneal fat weight (g) in the diet group when comparing control and DIO 
groups (14.9 ± 0.60 vs. 19.0 ± 1.58; p=0.0276) 61.9% IPF weight gained in DIO. 
 
 
 
 
 
 
 
 
  
 
Figure 34: Mean intra-peritoneal fat weight (g) after 16 weeks of DIO 
(n=8 control n=9 DIO). A significant increase was found in the mean intra-
peritoneal fat weight (g) in the diet group when comparing control and DIO 
groups (15.5 ± 1.28 vs. 28.0 ± 1.74; p<0.0001) 103.2% IPF weight gained in DIO 
group. 
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3.1.3 Fasting blood glucose and insulin levels  
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Figure 35: Fasting blood glucose levels (mmol/L) measured after 8 weeks 
of DIO. A significant increase was found in the blood glucose levels in the diet 
group when comparing control and DIO groups (n=8 Control; n=9 DIO)  
(3.78 ± 0.13 vs. 4.65 ± ; *p=0.0034) 
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Figure 36: Insulin levels measured after 8 weeks of DIO. A significant 
increase was found in the insulin levels in the diet group when comparing control 
and DIO groups (n=6 Control; n=6 DIO) (24.4 ± 4.74 vs. 54.1 ± 8.36: *p=0.0102) 
* 
* 
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3.1.4  HOMA index 
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 Figure 37: HOMA index calculated from insulin levels after 8 weeks of 
DIO. A significantly higher HOMA index was found in the diet group when 
comparing control and DIO groups (n=6 Control; n=6 DIO) (4.06 ± 0.98 vs. 11.9 ± 
1.82: *p=0.0037) 
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3.2 PKB/AKT EXPRESSION AND ACTIVATION BETWEEN NON-
INFARCTED AND INFARCTED ZONES COMPARED BETWEEN DIO 
AND CONTROL GROUPS 
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Figure 38: Phosphorylated PKB/Akt levels in the  infarcted and non-
infarcted zones in  both the diet and control group after 8 weeks of DIO 
(after 35 min regional ischaemia followed by 10 min reperfusion).  
A significant difference in the level of phosphorylated PKB/Akt was found 
between the  infarcted and non-infarcted zones in the control group (2.36 ± 0.50 
vs. 1.42 ± 0.28; p<0.05). No significant difference was found between the 
infarcted and non-infarcted zones in the diet group (1.83 ± 0.66 vs. 1.40 ± 0.46; 
p>0.05). 
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Figure 39: Total PKB/Akt expression in the  nfracted and non-infarcted 
zones in both the diet and control group after 8 weeks of DIO (after 35 min 
regional ischaemia followed by 10 min reperfusion). A significant difference in 
the total PKB/Akt levels was found between the  infarcted and non-infarcted 
zones in the control group (0.82 ± 0.02 vs. 0.96. ± 0.03; p<0.05). No significant 
difference was found between the  infarcted and non-infarcted zones in the diet 
group (0.81± 0.02 vs. 0.86 ± 0.05; p>0.05). 
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Figure 40: Phosphorylated/Total ratios in infarcted and non-infarcted 
zones between control and DIO groups (n=5 Control; n=6 Diet).  
No significant differences were found.  
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3.3 THE EXPRESSION OF THE REGULATORS OF METABOLIC GENES 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: PPAR-alpha expression in control and diet group after 8 weeks 
of DIO (n=4 per group). A significant difference was found in the level of PPAR 
alpha expression between the control and diet group (0.88 ± 0.06 vs. 1.25 ± 0.11; 
p=0.03). 
 
 
 
 
 
 
 
 
 
 
Figure 42: PPAR-alpha expression in control and diet group after 16 
weeks of DIO (n=4 per group). No significant differences were found when 
comparing the level of PPAR-alpha expression between control and DIO groups 
(0.69 ± 0.11 vs. 0.63 ± 0.122) 
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Figure 43: PGC-1 alpha expression in control and diet group after 8 
weeks of DIO (n=4 per group). A significant difference was found in the level of 
PGC-1 alpha expression between the control and diet group (1.16 ± 0.06 vs. 1.42 
± 0.12; p=0.03). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: PGC-1 alpha expression in control and diet group after 16 
weeks of DIO (n= 4 per group). No significant differences were found when 
comparing the level of PGC-1 alpha expression between control and DIO groups 
(0.83 ± 0.07 vs. 0.86 ± 0.11)  
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3.4 THE EXPRESSION OF METABOLIC PROTEINS 
 
3.4.1 GLUT 4 
 
 
 
 
 
 
 
 
 
Figure 45: GLUT 4 expression in control and diet group after 8 weeks of 
DIO (n=4 per group). No significant differences were found when comparing the 
level of GLUT 4 expression between control and DIO groups (2.65 ± 0.57 vs.  
2.62 ± 0.18; p=0.97). 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: GLUT 4 expression in control and diet group after 16 weeks of 
DIO (n=4 per group). No significant differences were found when comparing the 
level of GLUT 4 expression between control and DIO groups (0.99 ± 0.09 vs. 
0.77 ± 0.08, p=0.1130) 
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3.4.2 GLUT 1 
 
 
 
 
 
 
 
 
 
 
Figure 47: GLUT 1 expression in control and diet group after 8 weeks of 
DIO (n=4 per group). No significant differences were found when comparing the 
level of GLUT 1 expression between control and DIO groups (3.67 ± 1.04 vs.  
4.64 ± 0.48; p=0.43). 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: GLUT 1 expression in control and diet group after 16 weeks of 
DIO (n= 4 per group). No significant differences were found when comparing the 
level of GLUT 1 expression between control and DIO groups (0.84 ± 0.04 vs. 
0.80 ± 0.10) 
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3.4.3 Glycogen synthase kinase expression 
 
 
 
 
 
 
 
 
 
 
Figure 49: Phosphorylated GSK-3 in control and diet group after 8 weeks 
of DIO (n=4 per group) No significant differences were found when comparing 
the level of phosphorylated GSK-3 between control and DIO groups (1.26 ± 0.18 
vs.  1.51 ± 0.40; p=0.589). 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Phosphorylated GSK-3 in control and diet group after 16 
weeks of DIO (n=4 per group). No significant differences were found when 
comparing the level of phosphorylated GSK-3 between control and DIO groups 
(0.81 ± 0.04 vs. 0.81 ± 0.04; p=0.9293). 
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Figure 51:  Total GSK-3 expression in control and diet group after 8 weeks 
of DIO (n=4 per group). No significant differences were found when comparing 
the level of total GSK-3 expression between control and DIO groups (0.95 ± 0.05 
vs.  0.88 ± 0.12; p=0.611). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52:  Total GSK-3 expression in control and diet group after 16 
weeks of DIO (n=4 per group). No significant differences were found when 
comparing the level of total GSK-3 expression between control and DIO groups 
(0.80 ± 0.04 vs. 0.79 ± 0.02; p=0.8680). 
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3.4.4 PI-3 kinase expression 
 
 
 
 
 
 
 
 
 
 
Figure 53:  Phosphorylated PI 3- kinase in control and diet group after 8 
weeks of DIO (n=5 per group). No significant differences were found when 
comparing the level of phospho PI 3-kinase between the control and DIO groups 
(1.15 ± 0.06 vs.  0.92 ± 0.09; p=0.0716). 
 
 
 
 
 
 
 
 
 
 
Figure 54:  Phosphorylated PI 3-kinase in control and diet group after 16 
weeks of DIO (n=6 per group). A significant decrease was found in the level of 
phosphorylated PI 3 kinase in the diet group when comparing control and DIO 
groups (0.65 ± 0.08 vs. 0.42 ± 0.03; p=0.03) 
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Figure 55:  Total PI 3-kinase expression in control and diet group after 8 
weeks of DIO (n=5 per group). No significant differences were found when 
comparing the level of total PI-3 kinase expression between control and DIO 
groups (0.96 ± 0.05 vs.  1.01 ± 0.08; p=0.9814). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56:  Total PI 3-kinase expression in control and diet group after 16 
weeks of DIO (n=4 per group). No significant differences were found when 
comparing the level of total PI 3-kinase expression between control and DIO 
groups (0.75 ± 0.05 vs. 0.68 ± 0.08) p=0.5023. 
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3.4.5 PTEN expression 
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Figure 57:  Phosphorylated PTEN in control and diet group after 8 weeks 
of DIO (n=6 per group). No significant differences were found when comparing 
the level of phosphorylated PTEN between control and DIO groups (0.99 ± 0.08 
vs.  0.94 ± 0.13; p=0.6889). 
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Figure 58:  Phosphorylated PTEN in control and diet group after 16 weeks 
of DIO (n=6 per group). A significant decrease was found in the diet group when 
comparing the level of phosphorylated PTEN between control and DIO groups 
(1.09 ± 0.04 vs.  0.91 ± 0.05; p=0.0233). 
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Figure 59:  Total PTEN expression in control and diet group after 8 weeks 
of DIO (n=6 per group). No significant differences were found when comparing 
the level of total PTEN expression between control and DIO groups (0.86 ± 0.03 
vs. 0.86 ± 0.04; p=0.0506). 
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Figure 60:  Total PTEN expression in control and diet group after 16 
weeks of DIO (n=6 per group). No significant differences were found when 
comparing the level of total PTEN expression between control and DIO groups 
(0.83 ± 0.06 vs. 0.64 ± 0.06; p=0.953). 
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3.4.6 AMPK expression 
 
 
 
 
 
 
 
 
 
 
Figure 61:  Total AMPK expression in control and diet group after 8 weeks 
of DIO (n=4 per group). No significant differences were found when comparing 
the level of total AMPK expression between control and DIO groups (0.95 ± 0.05 
vs.  0.88 ± 0.12; p=0.611). 
 
 
 
 
 
 
 
 
 
 
 
Figure 62:  Total AMPK expression in control and diet group after 16 
weeks of DIO (n=6 per group). No significant differences were found when 
comparing the level of total AMPK expression between control and DIO groups 
(2.37 ± 0.29 vs. 2.69 ± 0.05; p=0.2954). 
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3.5 MITOCHONDRIAL FUNCTION 
  
3.5.1 Oxidative phosphorylation potential 
 
 
 
Figure 63: Oxygen consumption (mmol/ml) vs. time (seconds) for control and 
DIO groups, after 8 weeks of DIO, using glutamate as a substrate. 
 
 
 
Figure 64: Oxygen consumption (mmol/min) vs. time (seconds) for control and 
DIO groups, after 8 weeks of DIO, using palmitoyl-L-carnitine as a substrate. 
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Figure 65: Oxygen consumption (mmol/min) vs. time (seconds) for control and 
DIO groups after 16 weeks of DIO using glutamate as a substrate. 
 
 
 
Figure 66:  Oxygen consumption (mmol/min) vs. time (seconds) for control and 
DIO groups, after 16 weeks of DIO, using palmitoyl-L-carnitine as a substrate. 
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Table 17:  ADP/O ratio, State 3, State 4, RCI and oxidative 
phosphorylation rates of control and diet groups using 
glutamate as a substrate after 8 weeks of DIO 
 
  
ADP/O ratio: 
 
State 3: 
 
State 4: 
 
RCI: 
 
Oxphos rate: 
  
natoms O2/mg prot/min  
  
 
Control: 
 
2.89±0.10 
 
104.17±15.56 
 
11.62±3.68 
 
18.40±5.48 
 
299.17±46.23 
 
DIO: 
 
3.10±0.16 
 
107.18±16.19 
 
13.9±4.90 
 
24.46±10.69 
 
338.60± 59.11 
 
p-value: 
 
0.2931 
 
0.8950 
 
0.8950 
 
0.6035 
 
0.0875 
 
 
Table 18: ADP/O ratio, State 3, State 4, RCI and oxidative 
phosphorylation rates of control and diet groups using 
palmitoyl-L-carnitine as a substrate after 8 weeks of DIO 
 
  
ADP/O ratio: 
 
State 3: 
 
State 4: 
 
RCI: 
 
Oxphos rate: 
  
natoms O2/mg prot/min  
  
 
Control: 
 
9.44±4.57 
 
95.92±25.4 
 
13.92±5.41 
 
15.59±5.56 
 
538.05±144.7 
 
DIO: 
 
14.87±5.45 
 
59.83±10.17 
 
16.45±4.48 
 
5.07±1.34 
 
653.77± 201.2 
 
p-value: 
 
0.4626 
 
0.2168 
 
0.6652 
 
0.0955 
 
0.6506 
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Table 19: ADP/O ratio, State 3, State 4, RCI and oxidative 
phosphorylation rates of control and diet groups using 
glutamate as a substrate after 16 weeks of DIO 
 
  
ADP/O ratio: 
 
State 3: 
 
State 4: 
 
RCI: 
 
Oxphos rate: 
  
natoms O2/mg prot/min  
  
 
Control: 
 
2.67±0.12 
 
134.98±7.08 
 
9.92±0.36 
 
13.62±0.58 
 
361.31±24.42 
 
DIO: 
 
2.48±0.08 
 
125.46±8.96 
 
8.88±0.95 
 
14.77±1.11 
 
309.21± 22.59 
 
p-value: 
 
0.2016 
 
0.4203 
 
0.3244 
 
0.3773 
 
0.1433 
 
 
Table 20: ADP/O ratio, State 3, State 4, RCI and oxidative 
phosphorylation rates of control and diet groups using 
palmitoyl-L-carnitine as a substrate after 16 weeks of DIO 
 
  
ADP/O ratio: 
 
State 3: 
 
State 4: 
 
RCI: 
 
Oxphos rate: 
  
natoms O2/mg prot/min  
  
 
Control: 
 
5.84±1.57 
 
75.76±22.31 
 
6.39±0.89 
 
10.27±2.49 
 
251.11±42.84 
 
DIO: 
 
5.32±1.08 
 
66.59±18.42 
 
4.91±0.44 
 
13.73±4.06 
 
248.64± 36.48 
 
p-value: 
 
0.7899 
 
0.7568 
 
0.1585 
 
0.4808 
 
0.9657 
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3.5.2 Anoxia/reperfusion of isolated cardiac mitochondria 
 
 
 
 
 
 
 
 
 
 
Figure 67: The percentage recovery after 20 minutes of anoxia in control 
and diet groups using glutamate as a substrate. No significant differences 
were found when comparing the % recovery after 20 minutes of anoxia between 
control and diet groups (29.33 ± 8.47 vs. 24.74 ± 5.08; p=0.6505). 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: The percentage recovery after 20 minutes of anoxia in control 
and diet groups using palmitoyl-L-carnitine as a substrate. A significant 
increase was found in the diet group when comparing the % recovery after 20 
minutes of anoxia between control and diet groups (17.22 ± 5.1 vs. 78.46 ± 
23.22; p=0.0362) 
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3.5.3 Quantification of ATP production 
 
 
 
 
 
 
 
 
 
 
Figure 69: Amount of ATP produced during state 3 respiration. No 
significant difference was found when comparing the amount of ATP produced 
between control and DIO groups (2872.41 ± 497.2 vs. 2844.98 ± 566.7; 
p=0.9717) 
 
 
 
 
 
 
 
 
 
 
Figure 70: Amount of ATP produced during state 3 respiration by the 
control group when using either glutamate or palmitoyl-L-carnitine as 
substrates. No significant difference was found when comparing the amount of 
ATP produced by the control group when using either glutamate or palmitoyl-L-
carnitine as substrates (2895.28 ± 747.53 vs. 2849.55 ± 822.63; p=0.969) 
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Figure 71: Amount of ATP produced during state 3 respiration by the diet 
group when using either glutamate or palmitoyl-L-carnitine as substrates. 
No significant difference was found when comparing the amount of ATP 
produced by the diet group when using either glutamate or palmitoyl-L-carnitine 
as substrates (3419.69 ± 186.40 vs. 2270.27 ± 1113.85; p=0.3663) 
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3.6 ELECTRON TRANSPORT CHAIN COMPLEX ANALYSIS 
 
Table 21: State 3 respiration (natoms O2/mg prot/min): succinate, 
rotenone, oligomycin and CCCP when using glutamate as a 
substrate 
 
  
Succinate 
 
Rotenone 
 
Oligomycin 
 
CCCP 
 
Control 
 
297.45 ± 42.70 
 
72.43 ± 8.25 
 
58.46 ± 6.09 
 
10.47  ± 2.68 
 
DIO 
 
288.85 ± 33.14 
 
94.78 ± 11.18 
 
76.39 ±  9.56 
 
17.63  ± 1.14 
 
p-value 
 
0.8797 
 
0.1296 
 
0.1310 
 
0.0413 * 
 
*  P<0.05 significant difference 
 
Table 22: State 3 respiration (natoms O2/mg prot/min): succinate, 
rotenone, oligomycin, and CCP when using palmitoyl-L-
carnitine as a substrate 
 
  
Succinate 
 
Rotenone 
 
Oligomycin 
 
CCCP 
 
Control 
 
288.85 ± 33.14 
 
94.78 ± 11.18 
 
76.39 ± 9.56 
 
17.63  ± 1.14 
 
DIO 
 
152.16 ± 59.17 
 
73.21 ± 14.64 
 
55.19 ±  12.17 
 
16.87  ± 5.20 
 
p-value 
 
0.3841 
 
0.5933 
 
0.3262 
 
0.1699 
 
 
 
 
 
 
 
165 
3.7 CITRATE SYNTHASE ACTIVITY  
 
 
 
 
 
 
 
 
 
 
 
Figure 72: The level of citrate synthase activity (μmol/mgprot/min) in both 
the control and diet groups after 8 weeks of DIO. No significant difference in 
the level of citrate synthase activity was found between the control and diet group 
(0.53 ± 0.01 vs. 0.76 ± 0.11; p=0.166). 
 
 
 
 
 
 
 
 
 
 
Figure 73: The level of citrate synthase activity (μmol/mgprot/min) in 
control and diet groups after 16 weeks of DIO. A significant decrease was 
found in the level of citrate synthase activity in the diet group when comparing 
control and diet groups (0.099 ± 0.007 vs. 0.072 ± 0.005; p= 0.0085) 
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3.8 PYRUVATE DEHYDROGENASE ENZYME QUANTITY AND ACTIVITY 
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Figure 74:  The level of pyruvate dehydrogenase enzyme quantity after 8 
weeks of DIO. No significant difference was found between the quantity of PDH 
enzyme when comparing control and diet groups (0.007 ± 0.0006 vs. 0.01 ± 
0.0014; p= 0.165) 
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Figure 75: The level of pyruvate dehydrogenase enzyme quantity after 16 
weeks of DIO. No significant difference was found between the quantity of PDH 
enzyme when comparing control and diet groups (0.011 ± 0.0009 vs. 0.02 ± 
0.0021; p= 0.0835) 
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 Figure 76: The level of PDH activity measured after 8 weeks of DIO. No 
differences were found in PDH activity when comparing the control and DIO 
groups (0.09 ± 0.0022 vs. 0.10 ± 0.0024; p=0.6569) 
 
 
 
Figure 77: The level of PDH activity measured after 16 weeks of DIO. A 
significant increase in PDH activity was found in the diet group when comparing 
the control and DIO groups (0.11 ± 0.005 vs. 0.65 ± 0.0026; p<0.0001) 
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3.9 RELATIVE TRANSCRIPT LEVELS  MEASURED BY RT-PCR 
 
3.9.1  PDK 4 expression 
 
 
 
 
Figure 78: The level of PDK 4 expression after 8 weeks of DIO. The PDK 4 
expression was significantly up-regulated in the diet group (p=0.004 ±0.573-
2.081) 
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Figure 79: The level of PDK 4 expression after 16 weeks of DIO. No 
difference was found in the level of expression of PDK 4 when comparing control 
and DIO groups (p=0.608 ±1.262-2.295) 
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3.9.2  FAT/CD36 expression 
 
 
 
 
 
 
 
 Figure 80: The level of FAT/CD36 expression after 8 weeks of DIO. No 
difference was found in the expression of FAT/CD36 when comparing control and 
DIO groups (p=0.159 ±0.449-1.168) 
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 Figure 81: The level of FAT/CD36 expression after 16 weeks of DIO. NO 
differences were found in the level of expression of FAT/CD36 when comparing 
the control and DIO groups (p=0.520 ±0.445-1.306) 
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CHAPTER 4: DISCUSSION  
 
 
Cardiovascular disease is globally the primary cause of death in patients 
suffering from obesity and type-2 diabetes mellitus. The development of cardiac 
dysfunction and insulin resistance in these conditions are thought to be due to 
alterations in substrate metabolism [Coort et al. 2007]. We hypothesized that, in a 
rat model of diet-induced obesity, pathways involved in myocardial glucose 
utilization would be down regulated with simultaneous up regulation of FA 
utilization pathways and that this will lead to certain metabolic adaptations which 
will eventually become maladaptive. We therefore aimed to elucidate 
mitochondrial oxidative capacity and biogenesis, as well as signalling pathways 
involved in substrate utilization and energy production in rats on the obesity 
inducing diet for a period of 8 or 16 weeks.  
 
In our study we were able to establish that our model of diet-induced obesity 
displayed visceral obesity and insulin resistance with significantly elevated blood 
glucose and serum insulin levels.  
 
The intra-peritoneal fat weight was measured and used as a measure of 
abdominal obesity in all of our animals. Measuring the IP fat weight was 
important because it is well documented that there is a close relationship 
between abdominal obesity and a range of metabolic risk factors for heart 
disease [Kissebah et al. 1982; Folsom et al. 2000; Chan et al. 1994; Poulliot et al. 
1992]. These risk factors include insulin resistance and diabetes. French 
physician Jean Vague was first to report an association between the obesity 
phenotype and diabetes [Vague 1956], which has sparked a multitude of 
epidemiological and physiological studies which have all confirmed the 
relationship between abdominal obesity and insulin resistance. It is important to 
note that environmental, biological or inherited factors that induce insulin 
resistance can also cause abdominal fat accumulation, and that the association 
between abdominal fat and insulin resistance does not prove causality  
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[Frayn 2000]. A link between abdominal fat, fatty acid metabolism and insulin 
resistance has been suggested and is supported by observations that basal 
whole body FFA flux rates are increased in upper body obese subjects when 
compared to lower-body obese and lean subjects [Horowitz et al. 1999; Jensen 
et al. 1989], and the fact that diet-induced weight loss can decrease whole-body 
FFA flux and improve insulin sensitivity [Klein et al. 1996]. The fact that we found 
a significant increase in the IPF weight in the obese animals is a good indication 
that the diet was adequate in producing visceral obesity and that our diet-induced 
obese model may also be insulin resistant.  
 
4.1 Early and progressed metabolic remodelling in response to obesity  
 
In the presence of metabolic dysregulation as can be seen in the case of obesity 
and insulin resistance the heart responds to the changes in its environment by 
making specific metabolic alterations to favour the production of energy in order 
to maintain normal cardiac function. This phenomenon is often referred to in 
literature as metabolic adaptation. Metabolic adaptation in the case of obesity 
and insulin resistance aims to maintain cardiac function mainly by increasing the 
utilization of FAs, which in this scenario becomes the preferred substrate for 
energy production as glucose uptake and signalling pathways appear to be 
suppressed, by the increase in the availability of circulating FFAs [Young et al. 
2001]. As the regulators of the expression of metabolic genes in cardiomyocytes, 
PPAR alpha and PGC-1 alpha play a pivotal role in initiating this form of 
myocardial metabolic adaptation to obesity [Brown et al. 1995; Makinde et al. 
1998]. Literature suggests that this early metabolic adaptive response could 
possibly become maladaptive as the pathological accumulation of both glucose 
and FA metabolites will lead to the initiation of apoptosis, chronic activation of 
PKCs, ROS generation and contractile dysfunction [Young et al. 2001]. We were 
therefore particularly interested to investigate the effects of a prolonged high 
caloric diet (16 weeks DIO) on cardiac metabolism and more specifically how 
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efficient this so-called metabolic adaptive response will remain. In addition, we 
studied how mitochondrial function would be influenced. 
 
Results from our study indicate an early adaptive metabolic response. After 8 
weeks of DIO we observed significant elevations in the expression of PPAR 
alpha and PGC-1 alpha in the diet group. This confirms that an increase in the 
availability of circulating FFAs, based on the increase in visceral obesity, sparked 
an early metabolic adaptive response by increasing the expression of these two 
regulators of the expression of metabolic genes in the heart. Consequently we 
wanted to investigate how the expression of key metabolic proteins involved in 
both FA metabolism as well as glucose metabolism had been affected by this  
increase in the expression of PPAR alpha and PGC-1 alpha as well as the 
increase in FAs and the presence of insulin resistance, which of course will 
compromise glucose metabolism both at the level of glucose uptake i.e. defective 
insulin signalling, as well as at the level of the pyruvate dehydrogenase complex, 
which catalyzes the committed step for glucose oxidation [Young et al. 2002]. It 
appears however that after 16 weeks of diet, the hearts had apparently adapted 
metabolically to the increased levels of FAs and were able to maintain cardiac 
function. The early changes in the expression of PPAR alpha and PGC-1 alpha 
were now not noticeable which corroborates the findings of Young et al. 2001. 
 
We were able to observe some interesting metabolic changes that once again 
indicate an early adaptive metabolic response i.e. an increase in the expression 
of PDK 4 in the diet group after 8 weeks of DIO, as well as slightly compromised 
insulin signalling pathway at a later stage in the diet i.e. a decrease in the 
phosphorylation of PTEN and PI 3 kinase as well as an unexpected increase in 
the activity of PDH in the diet group after 16 weeks of DIO.  
 
Studies show that in states associated with decreased cardiac glucose utilization 
and increased rates of lipid oxidation, the activity and expression of PDK 4 in the 
adult rat heart is enhanced [Wu et al. 1998] and the up-regulation of cardiac PDK 
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4 protein expression is closely linked to an increased FA supply and/or oxidation 
[Sugden et al. 2000], which could be due to either the mobilization of 
endogenous triacylglycerol, as experienced during diabetes, or through an 
increased dietary lipid supply [Sugden et al. 2001].  
 
Long-chain FAs affect signalling pathways as well as gene expression. PPAR 
alpha plays an important role in the up-regulation of the expression of PDK 4, as 
the activation of PPAR alpha plays a role in the mediation of the effects of long-
chain FAs and/or their metabolites on the metabolism [Sugden et al. 2001]. Our 
findings substantiate this concept as the increase in the expression of PPAR 
alpha and PGC-1 alpha was accompanied by an increase in the level of PDK 4 
after 8 weeks of DIO. PDK 4 is also known to inhibit the pyruvate dehydrogenase 
enzyme complex, which is the enzyme responsible for catalyzing the committed 
step for carbohydrate oxidation, which will lead to a reduction in glucose 
oxidation [Young et al. 2002]. We however did not measure PDK 4 activity i.e. the 
amount of phosphorylated PDK 4, therefore we are unable to elucidate the role of 
PDK 4 in the activity of the PDH complex, especially after 16 weeks of DIO where 
we observed an increase in the activity of the PDH complex.  
 
An increase in the PDH activity in the diet group suggests that glucose oxidation 
is still functional and that after 16 weeks of DIO the PDH complex might not be 
negatively regulated by PDK 4 or the by-products of FA oxidation.  
 
PI 3 kinase is a key regulator of cell survival and growth and is responsible for 
the activation of PKB/Akt which in turn activates prosurvival substrates. PI 3 
kinase is also negatively regulated by PTEN which will affect the possible 
cardioprotective effects of PKB/Akt [Oudit and Penninger 2009]. The activity of 
PTEN is down regulated by phosphorylation, therefore a decrease in the 
phosphorylation of PTEN in the diet group implies that there is significantly more 
activation of apoptotic pathways in the diet group than in the control group after 
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16 weeks of DIO. Similarly decreased phosphorylation of PI 3 kinase indicates a 
reduction in the level of protection via the activation of survival pathways.  
 
In a pilot study we determined infarct size in hearts exposed to 
ischaemia/reperfusion after 8 weeks of DIO and found smaller infarcts than in 
control-fed animals. We therefore measured PKB/Akt expression and activity but 
could find no difference in the expression or activity of PKB/Akt in the infarcted or 
non-infarcted zones of the control and diet groups. PKB/Akt, as previously 
mentioned, has been implicated as a key role player in cardioprotection however 
these results indicate that PKB/Akt may not have been involved in the activation 
of survival pathways resulting in smaller infarct development. There was no 
change in the expression or activity of the up-stream activator of PKB/Akt, PI 3 
kinase, as well as the regulator of these two proteins, PTEN after 8 weeks of diet. 
 
We observed no other changes in the expression of the metabolic proteins that 
we investigated at the early, 8 week stage. Because changes may occur at a 
later stage, we investigated the protein expression profiles after 16 weeks on 
diet. Even after 16 weeks we observed no other changes other than the changes 
in PTEN, PI 3 kinase and PDH activity. There was also no other differences with 
regard to the expression of proteins involved in glucose and FA metabolism. We 
speculate that this could be because the metabolism has adapted and is now 
able to cope under the stresses of increased FAs and potential compromised 
glucose oxidation to maintain cardiac function.  
 
We did not measure the translocation of key proteins involved in glucose and FA 
uptake i.e. GLUT 4 and FAT/CD36. It is therefore possible that although we did 
not observe a difference in the total expression of GLUT 4 and FAT/CD36 that 
these two transporters may be facilitators in the transition of the utilization of FAs 
as preferred substrate since GLUT 4 might be sequestered in vesicles in the 
cytoplasm, which will ultimately lead to a reduction in glucose uptake, and 
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FAT/CD36 transporters might be inserted in the plasma membrane where they 
can facilitate the transport of FAs into the cell. 
 
The uptake of Long-chain FAs has been shown to be up-regulated in cardiac 
myocytes from obese, pre-diabetic Zucker rats, and this increase in the uptake of 
FAs is associated with an increase in FAT/CD36 on the cell surface and not an 
increase in the total expression of FAT/CD36 [Luiken et al. 2001]. Whereas in 
this obese and pre-diabetic state GLUT 4 is retained in intracellular storage 
compartments [Goodyear and Kahn 1998, Luiken et al. 2001]. Furthermore the 
translocation of FAT/CD36 from the intracellular storage compartment to the 
membrane has been shown to rapidly up-regulate the uptake of FAs into heart 
muscle [Glatz et al. 2010]. 
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Figure 82: The uptake of fatty acids and glucose by cardiac muscle is increased 
through the translocation of specific transport proteins i.e. GLUT 4 and 
FAT/CD36 respectively in response to insulin stimulation or increased contractile 
activity [Glatz et al. 2010] 
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Figure 83: Schematic representation of FAT/CD36 and GLUT 4 translocation 
in healthy (top) and insulin resistant (bottom) cardiac muscle [Glatz et al. 2010] 
 
It has been shown that in healthy heart tissue, GLUT 4 and FAT/CD36 are 
distributed equally between the intracellular storage compartments and the 
sarcolemma. This distribution of glucose and FA transporters is disturbed in the 
insulin-resistant state so that there is an increase in the translocation of 
FAT/CD36 to the membrane which results in an increase in FA uptake and the 
production of FA metabolites, which will interfere with and inhibit insulin signalling 
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and in doing so reduce the translocation of GLUT 4 to the sarcolemMa resulting 
in reduced glucose uptake [Glatz et al. 2010] 
 
Although we did not measure AMPK activity, it has been suggested the AMPK 
acts as a fuel gauge and plays a major role in the maintenance of intracellular 
energy balance [Cantó and Auwerx 2009]. AMPK is known to be activated in 
response to alterations in the AMP/ATP ratio and then acts to restore energy 
balance by up-regulating catabolic pathways which produce ATP and down-
regulating anabolic pathways that utilizes ATP [Cantó and Auwerx 2009]. PGC-1 
alpha has also been implicated as a possible mediator of AMPK-induced gene 
expression. The latter requires PGC-1 alpha activity in order to modulate the 
expression of key proteins involved in mitochondrial and glucose metabolism 
[Jager et al. 2007]. It has been shown that AMPK activation leads to an increase 
in the expression of PGC-1 alpha [Suwa et al. 2003; Terada et al. 2002] and can 
directly interact and phosphorylate PGC-1 alpha, which appears to increase the 
transcriptional activity of PGC-1 alpha [Jager et al. 2007]. Together with the 
elevated uptake of FAs into the heart, enhanced activity of AMPK may also be 
responsible for the early upregulation of PGC-1 alpha.  
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To summarize the expression of the metabolic proteins involved in both glucose 
and FA oxidation: 
 
Table 23: Summary of results 
 
 8 weeks DIO 16 weeks DIO 
 Total Phospho Total Phospho 
PPAR alpha UP - x - 
PGC-1 alpha UP - x - 
GLUT 1 x x x x 
GLUT 4 x x x x 
GSK-3 x x x x 
PKB/Akt x x NM NM 
PTEN x x x DOWN 
PI 3 kinase x x x DOWN 
PDK 4 UP NM x NM 
AMPK x NM x NM 
FAT/CD36 x NM x NM 
 
UP  (Up regulated in the diet group) 
DOWN (Down regulated in the diet group) 
x  (No difference in expression between the two groups) 
-  (Not able to measure) 
NM  (Not measured) 
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4.2 The role of mitochondria in the myocardial adaptive response 
 
Mitochondria play a putative role in the energetics of the heart. Oxidative 
phosphorylation is one of the main role players in the aerobic production of 
energy and relies on the availability of NADH, FADH2 and succinate, produced by 
the citric acid cycle, which uses acetyl-CoA from glucose and FA oxidation 
[Shiojima and Walsh 2006].  Therefore we suspected that if glucose or FA 
oxidation is altered in any way it should affect the oxidative phosphorylation 
potential of the mitochondria. Furthermore, as previously stated, mitochondrial 
biogenesis has been implicated as a key role player in cardioprotection in the 
insulin resistant heart. Therefore it was crucial that we investigated mitochondrial 
function and biogenesis in these obese and insulin resistant animals.  
 
In our study, on isolated mitochondria, we found no irregularities with regards to 
mitochondrial function after 8 weeks of DIO. We could find no differences in the 
oxidative phosphorylation rate and associated measures such as state 3 and 
state 4 respiration, the ADP/O ratio and the respiratory control index (RCI) as 
well as the respiration curves generated by an oxygraph between the control and 
diet groups using either glutamate or palmitoyl-L-carnitine as a substrate. The 
same was found after 16 weeks of DIO. An interesting observation was that the 
ADP/O ratios were higher in both the control and DIO groups when palmitoyl-L-
carnitine was used as a substrate. Since the ADP/O ratio indicates the 
phosphorylation of ADP for every atom of oxygen used, it appears as though 
more ADP molecules are phosphorylated per atom of oxygen i.e. more ATP is 
being produced per atom of oxygen when given the FA as a substrate.   Based 
on these results it appears as though these mitochondria are functioning well 
under the circumstances as there are no apparent signs of reduced mitochondrial 
oxidative capacity.  
 
We were unable to find any variation in the oxidative capacity of isolated 
mitochondria from these obese animals. It would be ideal to measure the 
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respiratory rates in the two specialized mitochondrial populations i.e. 
subsarcolemmal and intermyofibrillar mitochondria present in cardiac muscle 
[Palmer et al. 1977] The study by Iossa et al. 2002 showed that there is in fact a 
difference in the respiratory rates, regardless of the substrate used, between the 
two populations with the intermyofibrillar mitochondria showing higher state 3 and 
4 rates. The method that we used to isolate mitochondria selects for only the 
subsarcolemmal mitochondria.  
 
We then investigated the so-called mitochondrial biogenetic response i.e. PPAR 
alpha-PGC-1 alpha stimulated mitochondrial biogenesis. The expression of PGC-
1 alpha and PPAR alpha was significantly elevated in the diet group after 8 
weeks of DIO. PPAR alpha and PGC-1 alpha are known to integrate 
physiological signals and to enhance mitochondrial biogenesis and oxidative 
function [Puigserver et al. 1998, Wu et al. 2006]. We therefore expected to 
observe a mitochondrial biogenetic response i.e. an increase in citrate synthase 
activity, which is a measure of the number of mitochondria per mg of protein. 
Citrate synthase activity has been shown to be a sign of the expression of 
nuclear mitochondrial proteins, and is therefore used as a marker of 
mitochondrial content [Wang et al. 1999]. However, we could find no difference in 
the level of citrate synthase activity between the two groups. This could once 
again be because it is simply too early in the diet for us to see a significant 
change in the level of citrate synthase activity, since mitochondrial biogenesis is 
a complicated process that entails the synthesis, import, and incorporation of 
proteins and lipids to the existing mitochondrial reticulum and the replication of 
the mitochondrial genome i.e. the coordinated transcription of all of the 
mitochondrial genes in the nucleus and in the mitochondria [Hock and Kralli 
2009]. After 16 weeks of DIO however we observed a significant reduction in the 
citrate synthase activity in the diet group. Despite the decreased level of citrate 
synthase the mitochondria from these obese hearts had a significantly higher % 
recovery after anoxia reperfusion experiments, when given palmitoyl-L-carnitine 
as a substrate, and showed no signs of malfunctioning of the electron transport 
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chain. Additionally there was no difference in the amount of ATP produced by the 
mitochondria during state 3 respiration when compared to mitochondria from age 
matched control-fed animals.  
 
Contrary to our findings a study using skeletal muscle mitochondria showed that 
when young Wistar rats were fed a high-fat diet, an adaptive increase in whole 
body lipid utilization takes place as well as a significant increase in state 3 and 
state 4 lipid-supported respiration, and a selective increase in the activity of 
enzymes of the FA oxidation pathway which we did not measure in our study 
[Iossa et al. 2002]. However similar to our findings they also found no variation in 
mitochondrial protein mass or citrate synthase activity [Iossa et al. 2002].  
 
Based on these results it appears as though the mitochondria from the obese 
hearts were able to utilize the FA as a substrate more effectively during anoxia. 
Under normal conditions the heart preferentially utilizes FAs as a substrate for 
energy metabolism as it produces more ATP per molecule than glucose 
[Wallhaus et al. 2001]. However theoretical calculations of ATP yield per oxygen 
molecule consumed show that FAs are less efficient fuel than glucose. It is also 
calculated that shifting from 100% palmitate to 100% glucose as a substrate 
would increase the production of ATP by between 12-14% [Morrow and Givertz 
2005].  
 
Thus in an insulin resistant or diabetic heart where FAs are the preferred source 
of fuel more oxygen is required to generate the same amount of ATP compared 
with a healthy heart. And as cardiac work load does not change, the higher 
oxygen cost for ATP generation would eventually lead to an impairment of 
cardiac efficiency [Bugger and Abel 2008].  
 
Our results indicate that the mitochondria were able to utilize the FAs more 
efficiently than the glutamate, however this was under ideal in vitro conditions 
with ample oxygen supply. This could possibly mean that the metabolic 
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adaptation, which favours FA oxidation, could be beneficial for the heart at this 
stage of obesity instead of being detrimental. 
 
Mitochondrial biogenesis does not appear to play a significant role in the adaptive 
response of the heart as we could find no increase in mitochondrial number, 
however according to Duncan et al. (2007) early mitochondrial biogenesis occurs 
in the interfibrillar mitochondria, which we did not isolate. Our study may 
therefore have missed this.  
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CHAPTER 5: CONCLUSION 
 
We were able to establish that our model of diet-induced obesity displayed 
visceral obesity as well as insulin resistance with concomitant increased blood 
glucose and serum insulin levels and HOMA index. 
 
Early changes in the diet were depicted by a significant increase in the 
expression of PPAR alpha, PGC-1 alpha and PDK 4 after 8 weeks of DIO. There 
was no difference in the expression of any of the other metabolic proteins, 
involved in glucose and FA oxidation, that we investigated, which could possibly 
be attributed to the fact that it is too early in the diet to observe significant 
alterations in the metabolic profile. Similarly we observed no differences in the 
oxidative capacity of the mitochondria between the two groups, with no change in 
the level of citrate synthase activity.  
 
After 16 weeks of DIO we found a significant decrease in the phosphorylation of 
PI 3 kinase and PTEN which suggests compromised glucose oxidation. However 
mitochondria from the diet group displayed a significantly higher % recovery after 
anoxia/reperfusion experiments when using palmitoyl-L-carnitine, showed no 
malfunctioning of the electron transport chain and had a significantly higher level 
of PDH complex activity despite the fact that these obese animals had 
significantly less mitochondria.  
 
We therefore conclude that the hearts from these obese and insulin resistant rats 
are coping well and have adapted metabolically to compensate for any reduction 
in glucose oxidation. It is plausible that this beneficial initial adaptive response 
will eventually result in the occurrence of specific maladaptations as obesity, 
insulin resistance and diabetes progresses or if additional stresses such as 
hypertension is placed on the heart [Norton et al. 2009, Majane et al. 2009]. 
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